

INFORMAZIONI PERSONALI

Nome

Indirizzo privato

Telefono (casa)

Telefono (lavorativo)

Cellulare

Fax

E-mail

Nazionalità

Codice fiscale

NALDI LUIGI**ESPERIENZA LAVORATIVA**

- Date (da – a)
 - Nome e indirizzo del datore di lavoro
 - Tipo di azienda o settore
 - Tipo di impiego
 - Principali mansioni e responsabilità

 - Date (da – a)
 - Nome e indirizzo del datore di lavoro
 - Tipo di azienda o settore
 - Tipo di impiego

 - Data (da – a)
 - Nome dell'Ente e riconoscimento

 - Date (da – a)
 - Nome e indirizzo del datore di lavoro
 - Tipo di azienda o settore
 - Tipo di impiego
 - Principali mansioni e responsabilità

 - Date (da – a)
 - Nome e indirizzo del datore di lavoro
 - Tipo di azienda o settore
 - Tipo di impiego
 - Principali mansioni e responsabilità

 - Date (da – a)
 - Nome e indirizzo del datore di lavoro
 - Tipo di azienda o settore
 - Tipo di impiego
 - Principali mansioni e responsabilità

 - Date (da – a)
 - Nome e indirizzo del datore di lavoro
 - Tipo di azienda o settore
 - Tipo di impiego
 - Principali mansioni e responsabilità

 - Date (da – a)
 - Nome e indirizzo del datore di lavoro
 - Tipo di azienda o settore
 - Principali mansioni e responsabilità
- luglio 2017 -**
Ospedale San Bortolo, AULSS 8 - Vicenza
Polo ospedaliero
Direttore, Unità complessa di Dermatologia
Coordinamento e organizzazione dell'attività clinica e rapporto con l'amministrazione
- Settembre 2014-a tutt'oggi**
Clinica Dermatologica, Insospital, Università di Berna (Svizzera)
Ospedale Universitario
Consulente per i programmi di ricerca
- 2013-**
MIUR - Abilitazione nazionale al Ruolo Universitario di Professore ordinario nella Disciplina di Dermatologia
- 31 luglio 1999-2 luglio 2017**
Azienda Ospedaliera Ospedali Riuniti di Bergamo (dal gennaio 2013, Azienda Ospedaliera Papa Giovanni XXIII)
Azienda Sanitaria Ospedaliera
Dirigente medico a rapporto esclusivo, disciplina dermatologia e venereologia
Responsabile ambulatorio di riferimento per la psoriasi moderata-grave, responsabile ambulatorio di dermatologia del trapianto e responsabile ambulatorio per la valutazione delle complicanze cutanee nel paziente oncologico.
- gennaio 1999-giugno 2001**
Azienda Ospedaliera Ospedali Riuniti di Bergamo
Azienda Sanitaria Ospedaliera
Dirigente medico a rapporto esclusivo, disciplina dermatologia e venereologia
Responsabile, Unità funzionale di Farmacologia Clinica ed Epidemiologia
- 6 dicembre 1996- 30 luglio 1999**
Azienda Ospedaliera Ospedali Riuniti di Bergamo
Azienda Sanitaria Ospedaliera
Dirigente medico di primo livello, disciplina dermatologia e venereologia
Responsabile ambulatorio per le neoplasie epiteliali, dell'ambulatorio di dermatologia del trapianto, responsabile dell'ambulatorio dei linfomi cutanei, responsabile coordinamento Gruppo Italiano Studi Epidemiologici in Dermatologia (GISSED)
- 5 maggio 1993- 5 dicembre 1996**
Azienda Ospedaliera Ospedali Riuniti di Bergamo
Azienda Sanitaria Ospedaliera

- Tipo di impiego
- Principali mansioni e responsabilità

Aiuto corresponsabile ospedaliero, disciplina dermatologia e venereologia
 Responsabile ambulatorio per le neoplasie epiteliali, dell'ambulatorio di dermatologia del trapianto, responsabile dell'ambulatorio dei linfomi cutanei, responsabile coordinamento Gruppo Italiano Studi Epidemiologici in Dermatologia (GISED)

- Date (da – a)
- Nome e indirizzo del datore di lavoro
 - Tipo di azienda o settore
 - Tipo di impiego
- Principali mansioni e responsabilità

2 maggio 1988- 4 maggio 1993

Azienda Ospedaliera Ospedali Riuniti di Bergamo
 Azienda Sanitaria Ospedaliera
 Assistente medico, disciplina dermatologia e venereologia
 Attività clinica in reparto di degenza e ambulatoriale, responsabile coordinamento Gruppo Italiano Studi Epidemiologici in Dermatologia (GISED)

- Date (da – a)
- Nome e indirizzo del datore di lavoro
 - Tipo di azienda o settore
 - Tipo di impiego
- Principali mansioni e responsabilità

Settembre 1987- aprile 1988

ASL di Bergamo
 Azienda sanitaria locale
 Medicina convenzionata
 Incarico di medico di medicina generale convenzionata, ambito Curno-Mozzo (oltre 1000 assistiti)

- Date (da – a)
- Nome e indirizzo del datore di lavoro
 - Tipo di azienda o settore
 - Tipo di impiego
- Principali mansioni e responsabilità

Dicembre 1985 - agosto 1987

ASL di Bergamo
 Azienda sanitaria locale
 Servizio di guardia medica notturna, prefestiva e festiva
 -

- Date (da – a)
- Nome e indirizzo del datore di lavoro
 - Tipo di azienda o settore
 - Tipo di impiego
- Principali mansioni e responsabilità

Gennaio 1984-giugno 1986

Istituto di Ricerche Farmacologiche M. Negri, Milano
 Istituto di ricerche
 Borsista
 Attività di ricerca in farmacologia clinica ed epidemiologia con il coordinamento di un programma di studio caso-controllo di reazioni gravi a farmaci (emorragie digestive, insufficienza renale acuta, epatiti e colestasi farmaco-indotte, reazioni cutanee gravi da farmaco)

- Date (da – a)
- Nome e indirizzo del datore di lavoro
 - Tipo di azienda o settore
 - Tipo di impiego
- Principali mansioni e responsabilità

Ottobre 1981-ottobre 1982

Clinica del Lavoro, Università degli Studi di Pavia
 Clinica Universitaria
 Borsista universitario
 Attività di ricerca in allergologia respiratoria con particolare attenzione ai test di provocazione bronchiale
 -

INCARICHI PROFESSIONALI

- Date (da – a)
- Nome e indirizzo del datore di lavoro
 - Tipo di azienda o settore
 - Posizione
- Principali attività

Febbraio 2021-

WHO Uppsala Monitoring Centre
 Swedish Foundation
 Senior Advisor
 consulenza sull'analisi di segnali di reazioni da farmaco

- Date (da – a)
- Nome e indirizzo del datore di lavoro
 - Tipo di azienda o settore
 - Posizione
- Principali attività

Aprile 2020-

Innovative Medicine Initiative (IMI)
 EU public-private partnership funding health research and innovation
 Independent expert
 consulenza

- Date (da – a)
- Nome e indirizzo del datore di lavoro
 - Tipo di azienda o settore
 - Posizione
- Principali attività

Aprile 2020-

PsoPROTECT
 Non-profit international registry per la pandemia da SARS-CoV2
 Membro dell'International Advisory Board
 consulenza

- Date (da – a)

2019-

- Nome e indirizzo del datore di lavoro
 - Tipo di azienda o settore
 - Posizione
 - Principali attività

 - Date (da – a)
 - Nome e indirizzo del datore di lavoro
 - Tipo di azienda o settore
 - Posizione
 - Principali attività

 - Date (da – a)
 - Nome e indirizzo del datore di lavoro
 - Tipo di azienda o settore
 - Posizione
 - Principali attività

 - Date (da – a)
 - Nome e indirizzo del datore di lavoro
 - Tipo di azienda o settore
 - Posizione
 - Principali attività

 - Date (da – a)
 - Nome e indirizzo del datore di lavoro
 - Tipo di azienda o settore
 - Posizione
 - Principali attività

 - Date (da – a)
 - Nome e indirizzo del datore di lavoro
 - Tipo di azienda o settore
 - Posizione
 - Principali attività

 - Date (da – a)
 - Nome e indirizzo del datore di lavoro
 - Tipo di azienda o settore
 - Posizione
 - Principali attività

 - Date (da – a)
 - Nome e indirizzo del datore di lavoro
 - Tipo di azienda o settore
 - Posizione
 - Principali attività
- EDF/Euroguiderm
Non-profit professional organization
Membro dell'Euroguiderm Method Board
consulenza
- 2019-**
Leo Foundation
Fondazione danese in ambito sanitario
Membro del Scientific Evaluation Committee
consulenza
- 2019**
Institut National du Cancer
Fondazione francese in ambito sanitario
Evaluator per l'edizione 2019 cancer research projects SHS-E-PH
consulenza
- 2019**
Rete Oncologica Veneta
Gruppo di Lavoro Regione Veneto
Membro gruppo di lavoro per PDTA tumore di Merkel
consulenza
- 2018-**
International Alliance of Dermatology Patient Organizations
Non-profit patient organization
Membro Scientific Advisory Board GRIDD
consulenza
- 2018**
Cosmetic Ingredient Review, Washington, USA
Agenzia indipendente
Consulente
consulenza sul rischio oncologico associato a tinture per capelli
- 2018-**
UCB
Azienda farmaceutica
Componente del Psoriasis Learning Plan Steering Committee
consulenza scientifica per il progetto
- 2017-**
Global Psoriasis Atlas

Componente del Project Steering Committee e dal 2021 membro del Scientific Advisory Board
referente scientifico per il progetto
- Marzo 2017**
EADV
Organizzazione europea
rappresentante dell'EADV all'EMA per la rivalutazione delle procedure di risk minimization per
l'impiego dei retinoidi
Valutazione dei dati e proposte migliorative
- Dicembre 2016-tutt'oggi**
International League of Dermatological Societies (ILDS)
Organizzazione internazionale
Special Adviser sui Farmaci essenziali per il liaison committee dell'ILDS con l'OMS
Valutazione dei farmaci essenziali in dermatologia

- Date (da – a)
 - Nome e indirizzo del datore di lavoro
 - Tipo di azienda o settore
 - Posizione
 - Principali attività
 - Date (da – a)
 - Nome e indirizzo del datore di lavoro
 - Tipo di azienda o settore
 - Posizione
 - Principali attività
 - Date (da – a)
 - Nome e indirizzo del datore di lavoro
 - Tipo di azienda o settore
 - Posizione
 - Principali attività
 - Date (da – a)
 - Nome e indirizzo del datore di lavoro
 - Tipo di azienda o settore
 - Posizione
 - Principali attività
 - Date (da – a)
 - Nome e indirizzo del datore di lavoro
 - Tipo di azienda o settore
 - Posizione
 - Principali attività
 - Date (da – a)
 - Nome e indirizzo del datore di lavoro
 - Tipo di azienda o settore
 - Posizione
 - Principali attività
 - Date (da – a)
 - Nome e indirizzo del datore di lavoro
 - Tipo di azienda o settore
 - Posizione
 - Principali attività
 - Date (da – a)
 - Nome e indirizzo del datore di lavoro
 - Tipo di azienda o settore
 - Posizione
 - Principali attività
- 2016, 2019**
 Ministère des Affaires Sociales et de la Santé, Francia
 -
 Referee programma INNOVARC
 Valutazione di progetti di ricerca per qualità scientifica, fattibilità, congruità del finanziamento
- Settembre 2012**
 Agenzia Sanitaria e Sociale Regionale – Regione Emilia-Romagna, area Governance ricerca
 -
 Esperto indipendente del programma “Alessandro Liberati Programme for Young Investigators – Call 2012”. Tale programma è promosso in collaborazione dall’Assessorato alla Sanità della regione Emilia Romagna e dalle università della stessa Regione, all’interno del Programma di ricerca Regione-Università – Area 1: Innovative Research.
 Valutazione di progetti di ricerca per qualità scientifica, fattibilità, congruità del finanziamento
- 2011-2012**
 Regione Emilia Romagna, Programma di ricerca Regione-Università
 -
 Esperto valutatore per il Programma di ricerca Regione-Università 2010-2012– Area 2 Progetti per il governo clinico
 Valutazione di progetti di ricerca per qualità scientifica, fattibilità, congruità del finanziamento
- Novembre 2010 – a tutt’oggi**
 Istituto Superiore Sanità
 Istituto pubblico di ricerca
 Esperto indipendente per lo sviluppo delle line-guida nazionali sulla psoriasi
- Novembre 2009 – 2010**
 Organizzazione Mondiale della Sanità (OMS)
 Organizzazione internazionale
 Esperto per l’XI revisione della WHO International Classification of Diseases (ICD)
 Revisione delle categorie dermatologiche da inserire nel sistema ICD
- Gennaio 2009-dicembre 2009**
 Regione Emilia Romagna, Giunta Regionale, Direzione Generale Sanità e Politiche del Farmaco
 -
 Componente Gruppo di Lavoro Farmaci Biologici in Dermatologia
 Sviluppo di raccomandazioni condivise per l’impiego dei farmaci e di attività di auditing
- 2008-2009**
 European Medicines Agency (EMA ora EMA)
 Agenzia governativa europea
 Membro dell’Advisory Group per l’implementazione dell’ European Network of Centres for Pharmaco-epidemiology and Pharmacovigilance (ENCEPP)
 Partecipazione come esperto all’avvio della rete europea ENCEPP nell’ambito dell’EMA
- novembre 2008 – gennaio 2009**
 Regione Emilia Romagna, Agenzia Sanitaria e Sociale Regionale
 Ente pubblico regionale
 Consulente metodologico per l’ottimizzazione dei progetti sottoposti al programma di Ricerca Regione-Università della Regione Emilia Romagna (RER)
- 2007**
 European Medicine Agency (EMA ora EMA)
 Agenzia governativa Comunità europea
 Esperto Pediatric Committee

- Posizione
- Principali attività

Evaluator per l'edizione 2004 cancer research projects consulenza

- Date (da – a)
- Nome e indirizzo del datore di lavoro
 - Tipo di azienda o settore
 - Posizione
 - Principali attività

Gennaio 1998-ottobre 1998

Istituto Dermatologico dell'Immacolata IRCCS Roma
Istituto di Ricovero e Cura a Carattere Scientifico
Consulenza regolata da una convenzione
Organizzazione di attività di ricerca clinica presso l'IRCCS

- Date (da – a)
- Nome e indirizzo del datore di lavoro
 - Tipo di azienda o settore
 - Posizione

1991-1998

Azienda Ospedaliera Ospedali Riuniti di Bergamo
Azienda Sanitaria Ospedaliera
Componente Commissione Terapeutica

ISTRUZIONE E FORMAZIONE

- Data (da – a)
- Nome e tipo di istituto di formazione
- Principali materie/ abilità professionali oggetto dello studio
 - Qualifica conseguita

2009

I.Re.F. Scuola di Direzione in Sanità. Corso di Formazione Manageriale per Dirigente Sanitario di Struttura Complessa presso l'Università Bocconi, Milano corso UCB DSCO 0901

-

Certificato di formazione manageriale

- Date (da – a)
- Nome e tipo di istituto di istruzione
 - Principali materie / abilità professionali oggetto dello studio
 - Qualifica conseguita

1987

Scuola di Specializzazione in Dermatologia Università di Pavia

-

Diploma di specializzazione

- Date (da – a)
- Nome e tipo di istituto di istruzione
 - Principali materie / abilità professionali oggetto dello studio
 - Qualifica conseguita

1984

Scuola di Specializzazione in Allergologia Università di Pavia

-

Diploma di specializzazione

- Date (da – a)
- Nome e tipo di istituto di istruzione
 - Principali materie / abilità professionali oggetto dello studio
 - Qualifica conseguita

1981

Facoltà di Medicina e Chirurgia, Università di Pavia

-

Laurea

- Date (da – a)
- Nome e tipo di istituto di istruzione
 - Principali materie / abilità professionali oggetto dello studio
 - Qualifica conseguita

1977

Scuola Politecnica di Design
Progettazione industriale, Grafica pubblicitaria

Diploma

- Date (da – a)
- Nome e tipo di istituto di istruzione
 - Principali materie / abilità professionali oggetto dello studio
 - Qualifica conseguita

1973

Liceo Ginnasio P. Sarpi, Bergamo

-

Diploma di Maturità

DIDATTICA

- Date (da – a)

2013-2017

- Nome e indirizzo del datore di lavoro
 - Tipo di azienda o settore
 - Tipo di impiego
 - Principali mansioni e responsabilità
- Università degli Studi di Milano Bicocca
Diploma universitario di Ostetricia
Professore a contratto
Didattica corso di Malattie Cutanee e Veneree
- 1 gennaio 2015-30 ottobre 2015**
Università di Maastricht
Corso di Laurea in Medicina e Chirurgia
Tutor
Coordinamento del progetto di scambio SCIP e HELP
- Date (da – a)
 - Nome e indirizzo del datore di lavoro
 - Tipo di azienda o settore
 - Tipo di impiego
 - Principali mansioni e responsabilità
- 2011-2018**
Università di Verona
Master di I Livello in Farmacovigilanza e Discipline Regolatorie del Farmaco
Docente
Lezioni sulle reazioni avverse dermatologiche
- Date (da – a)
 - Nome e indirizzo del datore di lavoro
 - Tipo di azienda o settore
 - Posizione
 - Principali mansioni e responsabilità
- 2011-2017**
Università di Milano-Bicocca
Master di II livello in medicina dei trapianti
Docente
Lezioni sulla dermatologia del trapianto
- Date (da – a)
 - Nome e indirizzo del datore di lavoro
 - Tipo di azienda o settore
 - Posizione
 - Principali mansioni e responsabilità
- Gennaio 2001-gennaio 2003**
Hopitaux Universitaires de Genève
Ospedale Cantonale svizzero universitario
Professeur invité Clinique de Dermatologie
Didattica agli studenti e agli specializzandi, collaborazione alle attività di ricerca
- Date (da – a)
 - Nome e indirizzo del datore di lavoro
 - Tipo di azienda o settore
 - Tipo di impiego
 - Principali mansioni e responsabilità
- Novembre 2000-giugno 2006**
Università degli Studi di Modena e Reggio Emilia
Scuola di specializzazione in Dermatologia
Professore a contratto
Didattica agli specializzandi sulla dermatoepidemiologia e la medicina delle prove di efficacia
- Date (da – a)
 - Nome e indirizzo del datore di lavoro
 - Tipo di azienda o settore
 - Tipo di impiego
 - Principali mansioni e responsabilità
- Novembre 1999-giugno 2000**
Università degli Studi di Milano
Diploma universitario di Infermiere, Ospedali Riuniti di Bergamo
Professore a contratto
Didattica corso di Farmacologia
- Date (da – a)
 - Nome e indirizzo del datore di lavoro
 - Tipo di azienda o settore
 - Tipo di impiego
 - Principali mansioni e responsabilità
- Novembre 1991-giugno 2003**
Università degli Studi di Milano
Scuola di specializzazione in Dermatologia
Professore a contratto
Didattica agli specializzandi sulla dermatoepidemiologia e la medicina delle prove di efficacia
- Date (da – a)
 - Nome e indirizzo del datore di lavoro
 - Tipo di azienda o settore
 - Tipo di impiego
 - Principali mansioni e responsabilità
- Settembre 2020-**
Università degli Studi di Parma
Scuola di specializzazione in Dermatologia
Professore a contratto
Didattica agli specializzandi sulla Dermatologia clinica e la public health in Dermatologia

RICHIESTA DI VALUTAZIONI IN AMBITO ACCADEMICO

- Data (da – a)
- Nome dell'istituzione
 - Ruolo
 - Attività

agosto 2007

Ben-Gurion University of Negev, Faculty of Health Sciences, Beer-Sheva (Israele)
Valutatore

Analisi dei meriti scientifici per la promozione del Dr. Daniel Vardy al rank di full Professor of Dermatology

- Data (da – a)
 - Nome dell'istituzione
 - Ruolo
 - Attività
- giugno 1996**
Harvard Medical School, Boston (USA)
Valutatore
Analisi dei meriti scientifici del Prof. Robert Stern per la promozione al rank di full Professor of Dermatology and Director of Epidemiology
- Data (da – a)
 - Nome dell'istituzione
 - Ruolo
 - Attività
- settembre 1995**
Università di Dresda, Germania
Valutatore
Analisi dei meriti scientifici del Prof. Peter Elsner per l'elezione a Direttore della Clinica Dermatologica
- Data (da – a)
 - Nome dell'istituzione
 - Ruolo
 - Attività
- settembre 1993**
Brown University, School of Medicine, Providence (USA)
Valutatore
Analisi dei meriti scientifici del Dr. Martin Weinstock per la promozione al rank di Associate Professor

VALUTAZIONE DI STUDENTI PHD

- Data (da – a)
 - Nome dell'istituzione
 - Ruolo
- Luglio 2006**
University of Queensland
External examination of the thesis of Dr. Lisa Hall
- Data (da – a)
 - Nome dell'istituzione
 - Ruolo
- Novembre 2019**
University of Bern Graduate School for Cellular and Biomedical Sciences
Member of the thesis committee Dr. Simone Cazzaniga
- Data (da – a)
 - Nome dell'istituzione
 - Ruolo
- Maggio 2021**
Division of Dermatology and Venereology, Department of Medicine , Solna Karolinska Institutet, Stockholm, Sweden
Opponent thesis Dr. Axel Svedbom
- Data (da – a)
 - Nome dell'istituzione
 - Ruolo
- Dicembre 2021**
University of Copenhagen, Faculty of Health and Medical sciences
Assessment Committee thesis Dr. Rune Kjærsgaard Andersen

SOCIETA' SCIENTIFICHE

- Date (da – a)
 - Titolo, Nome della Società Scientifica
- 2023-**
Presidente Eletto, Associazione Dermatologi Ospedalieri Italiani (ADOI)
- Date (da-a)
 - Titolo, Nome della Società Scientifica
- 2013-2017**
President, International Psoriasis Network
- Date (da – a)
 - Titolo, Nome della Società Scientifica
- aprile 2012-a tutt'oggi**
Councillor, International Psoriasis Council (IPC)
- Date (da – a)
 - Titolo, Nome della Società Scientifica
- Ottobre 2018-Ottobre 2021**
Consigliere, Associazione Dermatologi Ospedali Italiani (ADOI)
- Date (da – a)
 - Titolo, Nome della Società Scientifica
- 1995-a tutt'oggi**
Past-president (1995-98) e membro del comitato scientifico European Dermatoepidemiology Network (EDEN)

SOCIETA' SCIENTIFICHE APPARTENENZA

- Date (da – a)
- gennaio 2011-a tutt'oggi**

- Nome della Società Scientifica Socio, American Academy of Dermatology
- Date (da – a)
- Nome della Società Scientifica **2011-a tutt'oggi**
Socio, European Society of Dermatological Research (ESDR)
- Date (da – a)
- Nome della Società Scientifica **2010-a tutt'oggi**
Membro invitato, Group for Research and Assessment of Psoriasis and Psoriatic Arthritis – GRAPPA
- Date (da – a)
- Nome della Società Scientifica **2010-a tutt'oggi**
Membro invitato, UK Dermatology Trial Network
- Date (da – a)
- Nome della Società Scientifica **gennaio 2010-a tutt'oggi**
Socio, European Academy of Dermatology and Venereology (EADV)
- Date (da – a)
- Nome della Società Scientifica **2009-a tutt'oggi**
Socio, Società Italiana di Dermatologia medica, chirurgica, estetica e delle malattie a trasmissione sessuale (SIDEMAST)
- Date (da – a)
- Nome della Società Scientifica **gennaio 2009-2015**
Socio, Associazione Dermatologi Ospedalieri Italiani (ADOI)
- Date (da – a)
- Nome della Società Scientifica **febbraio 2002-a tutt'oggi**
Invited member European Dermatology Forum (EDF)
- Date (da – a)
- Nome della Società Scientifica **gennaio 2000-a tutt'oggi**
Socio Onorario, Société Française de Dermatologie

CAPACITÀ E COMPETENZE

PERSONALI

PRIMA LINGUA

Italiano

ALTRE LINGUE

- Capacità di lettura
- Capacità di scrittura
- Capacità di espressione orale

Inglese

Eccellente
Eccellente
Eccellente

Francese

Buona
Discreta
Discreta

CAPACITÀ E COMPETENZE

RELAZIONALI:

GESTIONE PROGETTI DI RICERCA

(SELEZIONE)

- Data (da – a)
- Nome del progetto **Maggio 2020- a tutt'oggi**
Progetto Clicca il neo-LILT
Lega Italiana Lotta Contro ai Tumori (LILT)
Coordinatore
Sviluppo e valutazione controllata di un programma di teledermatologia per la diagnosi precoce dei tumori cutanei in varie città italiane con particolare attenzione agli anziani
- Ente finanziatore
- Ruolo Ricoperto
- Finalità del progetto
- Data (da – a)
- Nome del progetto **Ottobre 2016- a tutt'oggi**
Progetto Clicca il neo
Fondazione Credito Bergamasco, Fondazione Banca Popolare di Bergamo, ATS Bergamo e ASST papa Giovanni XXIII
Coordinatore
Sviluppo e valutazione controllata di un programma di teledermatologia per la diagnosi precoce dei tumori cutanei
- Ente finanziatore
- Ruolo Ricoperto
- Finalità del progetto
- Data (da – a)
- Data (da – a)

- Nome del progetto PSONET
 - Ente finanziatore Agenzia italiana del Farmaco (AIFA) fino al 2010 – Sostenuto da un grant dell'European Academy of Dermatology and Venereology (EADV) nel 2011 e 2012
 - Ruolo Ricoperto Coordinatore nell'ambito del Centro Studi GISED
 - Finalità del progetto Costituzione di una rete di sorveglianza europea per la valutazione della sicurezza dei trattamenti sistemici nella psoriasi con particolare attenzione per la valutazione dei rischi di eventi infrequenti o rari
-
- Data (da – a) **2010-a tutt'oggi**
 - Nome del progetto Progetto ERC: Studio caso-controllo dei fattori di rischio per lo sviluppo della dermatite atopica nei bambini
 - Ente finanziatore Comunità Europea – Seventh Framework Programme, grant agreement 250290
 - Ruolo Ricoperto Responsabile dell'unità Centro Studi GISED
 - Finalità del progetto Valutare il ruolo di una esposizione precoce ad agenti infettivi nella prevenzione della dermatite atopica (ipotesi igienista)
-
- Data (da – a) **2005-2011**
 - Nome del progetto EDEN Fragrance Study
 - Ente finanziatore Research Institute of Fragrance materials (RIFM)
 - Ruolo Ricoperto Coordinatore nell'ambito del Centro Studi GISED
 - Finalità del progetto Verificare la prevalenza di allergie da contatto ai profumi e altri allergeni nella popolazione europea
-
- Data (da – a) **2010-2011**
 - Nome del progetto Strategie a lungo termine di gestione clinica della psoriasi e studio controllato pragmatico sull'efficacia di interventi non farmacologici nel controllo della malattia. Farmacoeconomia e linee guida
 - Ente finanziatore Regione Emilia Romagna
 - Ruolo Ricoperto Responsabile delle analisi attraverso il Centro Studi GISED
 - Finalità del progetto Valutare in uno studio controllato e randomizzato il ruolo di un intervento dietetico nel ridurre la gravità clinica della psoriasi
-
- Data (da – a) **2006-2012**
 - Nome del progetto Valutazione dell'impatto di strategie educative sull'uso di farmaci e sull'aderenza al trattamento in pazienti con psoriasi
 - Ente finanziatore Agenzia italiana del Farmaco (AIFA)
 - Ruolo Ricoperto Responsabile dell'unità Centro Studi GISED
 - Finalità del progetto Verificare in quale misura interventi educativi rivolti a pazienti con una patologia cronico-recidivante quale la psoriasi possano migliorare l'efficacia delle cure farmacologiche attualmente disponibili
-
- Data (da – a) **2006-2012**
 - Nome del progetto Farmaci biologici: profili di beneficio-rischio nella pratica clinica reumatologica e dermatologica
 - Ente finanziatore Agenzia italiana del Farmaco (AIFA)
 - Ruolo Ricoperto Responsabile dell'unità Centro Studi GISED
 - Finalità del progetto Valutare il beneficio rischio dei farmaci biologici anti-TNF rispetto ai farmaci convenzionali in reumatologia e dermatologia
-
- Data (da – a) **2005-2009**
 - Nome del progetto Psocare
 - Ente finanziatore Agenzia Italiana del Farmaco (AIFA)
 - Ruolo Ricoperto Coordinatore nell'ambito del Centro Studi GISED
 - Finalità del progetto Registro dei trattamenti sistemici per la psoriasi associato alla prescrizione degli stessi farmaci
-
- Data (da – a) **2001-2003**
 - Nome del progetto Realizzazione di una rete sperimentale per la promozione della salute degli stranieri immigrati regolari, irregolari e nomadi
 - Ente finanziatore Ministero della Sanità N. ICS.1,2/RF00.140-2001

• Ruolo Ricoperto	Responsabile di Unità
• Finalità del progetto	Realizzazione di una rete sperimentale per la promozione della salute degli stranieri immigrati regolari, irregolari e nomadi
• Data (da – a)	2001-2003
• Nome del progetto	Studio dei meccanismi di insorgenza e controllo della reazione infiammatoria in soggetti con eczema costituzionale
• Ente finanziatore	Ministero della Sanità N. ICS.1,2/RF00.143-2001
• Ruolo Ricoperto	Responsabile di Unità
• Finalità del progetto	Studio dei meccanismi di insorgenza e controllo della reazione infiammatoria in soggetti con eczema costituzionale
• Data (da – a)	2001-2004
• Nome del progetto	Registro europeo delle gravi reazioni avverse cutanee a farmaci e raccolta di campioni biologici (REGISCAR)
• Ente finanziatore	Comunità Europea (progetto n: QLRT-2001-01738)
• Ruolo Ricoperto	Responsabile di Unità
• Finalità del progetto	Studio sulla farmaco-epidemiologia, sorveglianza continua di nuovi farmaci e studio dei meccanismi immunologici di SCAR
• Data (da – a)	1997-2001
• Nome del progetto	EURO-SCAR Study
• Ente finanziatore	Comunità Europea (progetto n: BIOMED BMH1-CT92-1320)
• Ruolo Ricoperto	Responsabile di Unità
• Finalità del progetto	Studio multinazionale caso-controllo per la valutazione del rischio di Sindrome di Stevens-Johnson e Necrolisi Tossico Epidermica indotta da farmaci

Nota - Le attività di ricerca sono rivolte, in particolare, all'utilizzo degli strumenti dell'epidemiologia clinica per la comprensione dei fattori che influenzano la comparsa e la prognosi delle più rilevanti patologie dermatologiche, alla ricerca traslazionale nel campo delle malattie infiammatorie croniche (psoriasi, dermatite atopica) e dell'oncologia cutanea in particolare nel soggetto immunodepresso (trapiantato d'organo), allo sviluppo di una dermatologia basata sulle prove di efficacia (Evidence-Based Dermatology). Nei programmi di ricerca sono privilegiate modalità di collaborazione in reti multicentriche e multidisciplinari. Tra i risultati della ricerca si possono citare la comprensione del ruolo dei fattori ambientali nella psoriasi e la documentazione dell'impatto di una riduzione di peso nel miglioramento della malattia, lo studio dei fattori di rischio per le neoplasie cutanee nella popolazione italiana, la definizione del ruolo di HPV nello sviluppo delle neoplasie cutanee nel soggetto trapiantato, la quantificazione dei rischi farmacologici per gravi reazioni cutanee (inclusi il ruolo di alcuni polimorfismi genetici sulla suscettibilità), il perfezionamento della metodologia per valutare la sicurezza dei trattamenti attraverso i registri clinici.

CAPACITÀ E COMPETENZE ORGANIZZATIVE

Le attività cliniche e di ricerca riportate sopra comportano capacità organizzative. Di seguito si riportano ulteriori attività che implicano competenze organizzative

• Date (da – a)	2001-a tutt'oggi
Organizzazione	Centro Studi GISED Associazione non profit riconosciuta dalla Regione Lombardia e convenzionata con l'Università degli Studi di Milano (Centro Interuniversitario Thomas Chalmers)
• Posizione	Presidente
• Date (da – a)	2013-tutt'oggi
• Organizzazione	Global Burden of Disease (GBD) initiative, Washington University
• Posizione	Membro della rete collaborativa
• Date (da – a)	2011
• Organizzazione	European Clinical Research Infrastructure Network (ECRIN)
• Posizione	Membro del comitato degli esperti
• Date (da – a)	2011
• Organizzazione	Dystrophic Epidermolysis Bullosa Research Association (DEBRA)

- Posizione Expert Panel member

- Date (da – a) **2011-a tutt'oggi**
- Organizzazione Fondation René Touraine - Francia
- Posizione Membro del Comitato Scientifico

- Date (da – a) **2010 - a tutt'oggi**
- Organizzazione Psolar registry
- Posizione Membro del comitato consultivo

- Date (da – a) **2009**
- Organizzazione International Leagues of Dermatological Societies (ILDS)
- Posizione Member of the ILDS working group for the revision of the WHO essential drugs

- Date (da – a) **dicembre 2009 – a tutt'oggi**
- Organizzazione Swiss Society of Dermatology and Venereology
- Posizione Consulente per lo sviluppo del registro svizzero della psoriasi

- Date (da – a) **2001-2002**
- Organizzazione Università degli Studi di Siena
- Posizione Referente progetti presentati sul Piano di Ateneo per la Ricerca

- Date (da – a) **1997**
- Organizzazione National Psoriasis Foundation – USA
- Posizione Esperto referente

- Date (da – a) **1996-a tutt'oggi**
- Organizzazione Cochrane Skin Group, Cochrane Collaboration
- Posizione Editor

DIREZIONE RIVISTE E ALTRE ATTIVITA' EDITORIALI

- Data (da – a) 2012-
- Nome della rivista Editorial Board, Clinical Dermatology

- Data (da – a) 2011-
- Nome della rivista Section Editor, Current Dermatology Report

- Data (da – a) 2011-
- Nome della rivista Editorial Board, World Journal of Dermatology

- Data (da – a) 2009-
- Nome della rivista Editorial Board, Advances in Psoriasis and Inflammatory Skin Diseases

- Data (da – a) gennaio 2009-a tutt'oggi
- Nome della rivista Associate Editor, BMC Medical Research Methodology

- Data (da – a) 2008-tutt'oggi
- Nome della rivista Editorial Board Inflammation and Allergy – Drug Targets Journal

- Data (da – a) gennaio 2007-dicembre 2007
- Nome della rivista Founder and Editorial Board member, Dermatology Research and Practice

- Data (da – a) gennaio 2007-a tutt'oggi

• Nome della rivista	Associate Editor, Journal of Medical Case Report
• Data (da – a)	2007-a tutt'oggi
• Nome della rivista	Editorial Advisor, BMC Dermatology
• Data (da – a)	gennaio 2006-settembre 2012
• Nome della rivista	Associate Editor, Journal of Investigative Dermatology
• Data (da – a)	gennaio 2003-dicembre 2006
• Nome della rivista	Direttore, EBD – Scienza e cultura della pelle
• Data (da – a)	gennaio 2001-a tutt'oggi
• Nome della rivista	Editorial Advisor, BioMed Central
• Data (da – a)	2001-2006
• Nome della rivista	Membro Comitato Scientifico, Clinical Evidence, edizione italiana, issues 1-6
• Data (da – a)	gennaio 2000-dicembre 2006
• Nome della rivista	Comitato di Redazione, Giornale Italiano di Dermatologia e Venereologia
• Data (da – a)	gennaio 2000-a tutt'oggi
• Nome della rivista	Associate Editor, Dermatology
• Data (da – a)	gennaio 1999-dicembre 2006
• Nome della rivista	Scientific Board, Journal of the European Academy of Dermatology and Venereology
• Data (da – a)	dicembre 2014-a tutt'oggi
• Nome della rivista	Comitato Scientifico, Recenti Progressi in Medicina (Il Pensiero Scientifico editore)
• Data (da – a)	2014-a tutt'oggi
• Nome della rivista	Associate Editor, British Journal of Dermatology
• Data (da – a)	Novembre 2018-a tutt'oggi
• Nome della rivista	Editorial Board, Journal of the European Academy of Dermatology and Venereology
• Data (da – a)	2018-a tutt'oggi
• Nome della rivista	Advisory Board for Clinical Pharmacist and from August 2019 of the The Pharmaceutical Journal
Data (da – a)	2020-a tutt'oggi
Nome della rivista	Editor-in Chief, Dermatology Reports
Data (da-a)	2021-a tutt'oggi
Nome della rivista	Biologics

Attività di peer-reviewer per riviste mediche (anno di attività tra parentesi)

Acta Dermato-Venereologica (2007, 2016-22)
 American Journal of Clinical Dermatology (2017, 2021)
 Archives of Dermatology-JAMA Dermatology (1992-2022)
 Archives of Dermatological Research (2006,2009,2012,2020)
 Archives of Internal Medicine (2007)
 Dermatology (1992,1993,1999-2016, 2020-2021)
 Journal of the American Academy of Dermatology (1993, 1996,2002,2003,2004-2022)
 Journal of the European Academy of Dermatology and Venereology (1994,1996,1997, 1998,1999,2000- 2022)
 British Journal of Dermatology (1993, 1996,1997,1998,2002-2007, 2009-2022)
 Giornale Italiano di Dermatologia e Venereologia (1997,2010,2021)
 Annals of Rheumatic Diseases (1995,1997)
 Journal of Nephrology (1996,2006)

Drug and Therapeutics Bulletin (1998)
 Expert Opinion on Investigational Drugs (1997)
 Cancer (2000,2010)
 Case Report in Dermatology (2017)
 Journal of Investigative Dermatology (2000,2002,2003-2012,2014-2021)
 Exogenous Dermatology (2001,2005)
 Experimental Dermatology (2005,2009)
 Epilepsy (2003)
 International Journal of Cancer (2004,2005)
 JAAD Case Report (2017, 2019)
 Journal de Deutschen Dermatologischen Geellschaft (2005)
 Journal of Allergy and Clinical Immunology (2017,2020)
 Journal of Cosmetic and Laser Therapy (2017)
 Journal of Medical Economics (2017, 2019)
 Indian Journal of Dermatology, Venereology and Leprology (2004,2005-2007)
 Melanoma Research (2006-2008)
 International Archives of Allergy and Immunology (2007)
 JAMA (2007)
 Lancet (2007, 2009,2011,2014,2015)
 British Medical Journal (2006-2007, 2009, 2018, 2019, 2020)
 Pharmacoepidemiology and Drug Safety (2009)
 European Journal of Dermatology (2006,2007,2009)
 Clinical Experimental Dermatology (2007,2009)
 BMC Dermatology (2005,2008)
 BMC Cancer (2005)
 BMC Nursing (2010)
 Journal of Dermatological Science (2008)
 International Archives of Allergy and Immunology (2007)
 European Journal of Cancer (2005)
 PloS Medicine (2006,2018)
 Medical Science Monitor (2006)
 Preventive Medicine (2007)
 Journal of Medical Case Report (2012-2020)
 Therapeutics and Clinical Risk Management (2007)
 New England Journal of Medicine (2010,2011,2014)
 Medicine (2017, 2018,2019,2020)
 PLOS One (2014,2015,2017,2018,2021)
 Journal of Clinical Investigation (2017)
 European Journal of Internal Medicine (2019)
 Frontiers in Medicine (2020)

**CAPACITÀ E COMPETENZE
TECNICHE**

Sa operare con software per la gestione e l'analisi di dati epidemiologici (EpiLog, SPSS, EpiInfo)

**CAPACITÀ E COMPETENZE
ARTISTICHE**

Si è occupato di grafica e progettazione diplomandosi in Industrial Design alla Scuola Politecnica di Design di Milano. Si interessa di Medical Humanities e coordina il sito "Fior di pelle" repertorio di citazioni letterarie sul tema della pelle (www.fiordipelle.it) e il sito del Centro Studi GISSED che comprende una sezione "Arte e Pelle" (www.centrostudigised.it)

ALTRE CAPACITÀ E COMPETENZE

Ha partecipato in qualità di esperto ad alcuni programmi della televisione nazionale italiana (Elisir, RAI 3, Domenica In, RAI 1) e locali (Bergamo TV, TVA Vicenza). La sua opinione è stata citata in alcuni quotidiani e riviste nazionali (Il Sole 24 Ore, La Repubblica, Il Corriere della Sera, L'Espresso, Panorama, e altri) e internazionali (tra gli altri, El Mundo Salud, The Wall Street Journal, Chicago Tribune, Fox News). E' consulente per il giornale OK Salute

**PARTECIPAZIONI A CONGRESSI IN
QUALITÀ DI RELATORE INVITATO**

E' stato "guest speaker" o moderatore in oltre 250 congressi e convegni internazionali negli ultimi venti anni. Questi includono, tra gli altri, i meeting annuali dell'American Academy of Dermatology, quelli dell'European Academy of Dermatology and Venereology, i meeting annuali dell'European Society for Dermatological Research e tutte le edizioni del

Dermatology World Congress a partire dal 1997 e fino al 2019.

PUBBLICAZIONI

E' autore di un totale di 474 lavori scientifici (full paper) pubblicati su riviste "indicizzate" con i seguenti parametri di impatto: citations= 85394, indice di Hirsch (h-index)=94 (fonte, Google Scholar, 12 gennaio 2024). Si pone al 41^a posto nella classifica per h-index dei Top Italian Scientists per Clinical Sciences (fonte, <http://www.topitalianscientists.org>, luglio 2019).

I dati personali saranno trattati in ottemperanza a quanto richiesto dal Dgs 196/2003 e Regolamento Europeo 679/2016. Si attesta inoltre la consapevolezza del rispetto alle responsabilità connesse a dichiarazioni mendaci (DPR 445/2000 ar. 76)

Autorizzo il trattamento dei dati personali contenuti nel mio curriculum vitae in base all'art. 13 del D. Lgs. 196/2003 e all'art. 13 GDPR 679/16

Bergamo, 12-01-2024

Luigi Naldi

Luigi Naldi
12.01.2024
14:14:25
GMT+01:00



ALLEGATO - Elenco pubblicazioni

1. Pezzolo E, Schena D, Gambardella A, Rossi M, Barei F, Calzavara Pinton P, Girolomoni G, Naldi L, Ferrucci SM. Survival, efficacy and safety of tralokinumab after 32 and 52 weeks of treatment for moderate-to-severe atopic dermatitis in adults: A multicentre real-world study. *J Eur Acad Dermatol Venereol*. 2024;38:e11-e13.
2. Ferrucci S, Barei F, Tavecchio S, Marzano AV, Zussino M, Naldi L, Pezzolo E. Assessment of patient-reported outcomes at 24 weeks of treatment with tralokinumab for atopic dermatitis: a multicentric real-life experience. *J Dermatolog Treat*. 2023 Dec;34(1):2285243.
3. Brüggem MC, Walsh S, Ameri MM, et al. Management of Adult Patients With Drug Reaction With Eosinophilia and Systemic Symptoms: A Delphi-Based International Consensus. *JAMA Dermatol*. 2023 Nov 15:e234450. Epub ahead of print.
5. Pezzolo E, Sechi A, Tartaglia J, Naldi L. A critical evaluation of suitability of tralokinumab for treatment of moderate-to-severe atopic dermatitis in adolescents and adults. *Expert Rev Clin Immunol*. 2023 Nov 13. Epub ahead of print.
6. Naldi L. Socioeconomic status, biologics and all-cause mortality. *J Eur Acad Dermatol Venereol*. 2023;37:e1325.
7. Kwatra SG, Yosipovitch G, Legat FJ, et al.. Phase 3 Trial of Nemolizumab in Patients with Prurigo Nodularis. *N Engl J Med*. 2023;389:1579-1589.
8. Brüggem MC, Walsh S, Ameri MM, et al. Management of Adult Patients With Drug Reaction With Eosinophilia and Systemic Symptoms: A Delphi-Based International Consensus. *JAMA Dermatol*. 2023 Nov 15. Epub ahead of print.
9. Naldi L, Cassalia F. Actinic keratosis epidemiology: the good, the bad, and the ugly. *Br J Dermatol*. 2023 Oct 25:ljad395.
10. Heidemeyer K, May Lee M, Cazzaniga S, Yawalkar N, Naldi L. Palmoplantar Pustulosis: A Systematic Review of Risk Factors and Therapies. *Psoriasis (Auckl)*. 2023 Sep 22;13:33-58.
11. Garcia-Doval I, Rajan N, Hunter H, Frew J, Naldi L, Mellerio JE, Hay R. Clinical reports: the overarching home for case series and case reports in the BJD. *Br J Dermatol*. 2023 Aug 21. Epub ahead of print.
12. May Lee M, Naldi L, Piraccini BM, Starace M, Alessandrini A, Sechi A. Trichoscopy as a Tool to Evaluate Early Dissecting Cellulitis in Patients Affected by Hidradenitis Suppurativa: A Prospective Monocentric Observational Study. *Skin Appendage Disord*. 2023;9:275-279.
13. Naldi L, Garcia-Doval I, Williams HC. Nutritional Supplements and Hair Loss-Limitations to the Interpretation of Clinical Studies Before Implementation in Clinical Practice. *JAMA Dermatol*. 2023;159:892-893.
14. Pezzolo E, Gambardella A, Guanti M, Bianchelli T, Bertoldi A, Giacchetti A, Donini M, Argenziano G, Naldi L. Tralokinumab shows clinical improvement in patients with prurigo nodularis-like phenotype atopic dermatitis: A multicenter, prospective, open-label case series study. *J Am Acad Dermatol*. 2023;89:430-432.
15. May Lee M, Naldi L, Pierobon E, Leuzzi M, Sechi A. Florid cutaneous papillomatosis and acanthosis nigricans as cutaneous findings in a patient with ovarian carcinoma. *J Cosmet Dermatol*. 2023;22:2364-2366.
16. Naldi L, Ferrucci SM. Survival, efficacy and safety of tralokinumab after 32 and 52 weeks of treatment for moderate-to-severe atopic dermatitis in adults: A multicentre real-world study. *J Eur Acad Dermatol Venereol*. 2023 Jul 22. Epub ahead of print.
17. Sbidian E, Chaimani A, Guelimi R, Garcia-Doval I, Hua C, Hughes C, Naldi L, Kinberger M, Afach S, Le Cleach L. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. *Cochrane Database Syst Rev*. 2023 Jul 12;7(7):CD011535.

18. Naldi L. Socioeconomic status, biologics and all-cause mortality. *J Eur Acad Dermatol Venereol*. 2023 Jul 7. doi: 10.1111/jdv.19312. Epub ahead of print.
19. Freeman EE, Garcia-Doval I, Naldi L, Hay RJ. Three years on, COVID-19 and the skin: long-term impacts, emerging trends and clinical practice. *Br J Dermatol*. 2023;189:1-3.
20. Naldi L, Addis A. Biosimilars for the Treatment of Psoriasis-A Systematic Review of Clinical Trials and Observational Studies: Looking Beyond Single-Trial Evidence for a Valuable Choice. *JAMA Dermatol*. 2023;159:697-699.
21. Heidemeyer K, Kulac M, Sechi A, Cazzaniga S, Naldi L. Lasers for the treatment of psoriasis: a systematic review. *Expert Rev Clin Immunol*. 2023;19:717-744.
22. Heidemeyer K, Cazzaniga S, Dondi L, Ronconi G, Pedrini A, Bellatreccia A, Zhong Y, Martini N, Naldi L. Variables associated with joint involvement and development of a prediction rule for arthritis in patients with psoriasis. An analysis of the Italian PsoReal database. *J Am Acad Dermatol*. 2023;89:53-61.
23. Burlando M, Campione E, Cuccia A, Malara G, Naldi L, Prignano F, Zichichi L. Real-world use of dimethyl fumarate in patients with plaque psoriasis: a Delphi-based expert consensus. *Dermatol Reports*. 2022 Dec 29;15(2):9613.
24. Pezzolo E, Rossi M, Caroppo F, Bianchelli T, Belloni Fortina A, Giacchetti A, Calzavara Pinton P, Naldi L. Long-term drug survival of dupilumab and associated predictors in moderate-to-severe atopic dermatitis: A real-world prospective cohort study. *J Eur Acad Dermatol Venereol*. 2023;37(6):e757-e759.
25. Pezzolo E, Naldi L. Tralokinumab in the treatment of resistant atopic dermatitis: An open-label, retrospective case series study. *J Eur Acad Dermatol Venereol*. 2023;37(5):e644-e645.
26. Quirke-McFarlane S, Weinman J, Cook ES, Yiu et al. Nonadherence to systemic immune-modifying therapy in people with psoriasis during the COVID-19 pandemic: findings from a global cross-sectional survey. *Br J Dermatol*. 2023;188:610-617.
27. Cazzaniga S, Heidemeyer K, Naldi L; PsoReal study group. Phenotypes of Psoriasis in Patients in Need of Systemic Treatment, and Correlation with Personal Habits, Treatment History and Comorbidities: A Cross-sectional Latent Class Analysis of Data from the Italian PsoReal Registry. *Acta Derm Venereol*. 2023 Apr 4;103:adv5331.
28. Sechi A, Song J, Dell'Antonia M, Heidemeyer K, Piraccini BM, Starace M, Naldi L. Adverse events in patients treated with Jak-inhibitors for alopecia areata: A systematic review. *J Eur Acad Dermatol Venereol*. 2023 Apr 4. Epub ahead of print.
29. Cazzaniga S, Naldi L, Borradori L. Rituximab and risk of infections in patients with pemphigus: answers from a global population-based cohort study. *Br J Dermatol*. 2023;188:454-455.
30. Gnesotto L, Mioso G, Bardazzi F, Filippi F, Di Lernia V, Motolese A, Di Nuzzo S, Conti A, Arginelli F, Corazza M, Odorici G, Borghi A, Gisondi P, Naldi L, Dapavo P, Parodi A, Burlando M, Piaserico S. Dimethyl Fumarate Treatment in Patients with Moderate-to-Severe Psoriasis: A 52-week Real-life Study. *Acta Derm Venereol*. 2023 Mar 28;103:adv4526.
31. Hoxha A, Tomaselli T, Minicucci GM, Dall'Acqua J, Zardo D, Simioni P, Naldi L. Hypereosinophilic Syndrome Following the BNT162b2 (BioNTech/Pfizer) Vaccine Successfully Treated with Mepolizumab: A Case Report and Review of the Literature. *J Clin Med*. 2023 Mar 19;12(6):2376.
32. Massone C, Perasole A, Naldi L. Teledermatopathology on the ADOI platform and beyond. *Dermatol Reports*. 2023 Mar 10;15(1):9670.
33. Cazzaniga S, De Ponti L, Baratelli GM, Francione S, La Vecchia C, Di Landro A, Carugno A, Di Mercurio M, Germi L, Trevisan G, Fenaroli M, Capasso C, Pezza M, Dri P, Castelli E, Naldi L. Agreement on classification of clinical photographs of pigmentary lesions: exercise after a training course with young dermatologists. *Dermatol Reports*. 2022 Jul 14;15(1):9500.

34. Cazzaniga S, Heidemeyer K, Dondi L, Ronconi G, Pedrini A, Bellatreccia A, Zhong Y, Naldi L, Martini N. Prevalence of psoriatic arthritis among patients with psoriasis in Italy. *J Eur Acad Dermatol Venereol*. 2023 Mar;37(3):e306-e308.
35. Augustin M, Sommer R, Daudén E, Laws P, de Jong E, Fabbrocini G, Naldi L, Navarini A, Lambert J, Reguiat Z, Gerdes S, Massana E, Obis T, Kasujee I, Mrowietz U. Patient-reported well-being in value-based care using tildrakizumab in a real-world setting: protocol of a multinational, phase IV, 1-cohort prospective observational study (the POSITIVE study). *BMJ Open*. 2023 Feb 15;13(2):e060536.
36. Costanzo A, Bardazzi F, DE Simone C, Fabbrocini G, Foti C, Marzano AV, Naldi L, Parodi A, Prignano F, Girolomoni G. Pustular psoriasis with a focus on generalized pustular psoriasis: classification and diagnostic criteria. An Italian expert consensus. *Ital J Dermatol Venerol*. 2022;157:489-496.
37. Trevisan G, Germi L, Naldi L. Erythrodermic psoriasis improved by Tildrakizumab. *Dermatol Reports*. 2022 Nov 23;14(4):9448.
38. Pezzolo E, Naldi L. Tralokinumab in the treatment of resistant atopic dermatitis: An open-label, retrospective case series study. *J Eur Acad Dermatol Venereol*. 2022 Nov 20.
39. Cazzaniga S, Pezzolo E, Colombo P, Naldi L. Face mask use in the community and cutaneous reactions to them during the COVID-19 pandemic: results of a national survey in Italy. *Dermatol Reports*. 2022 Jan 26;14(3):9394.
40. Cusano F, Sampogna F, Brunasso Verneti AMG, et al. A consensus-based approach on the management of patients with both psoriasis and psoriatic arthritis in the dermatological and rheumatological settings in Italy: The ADOI PSO-Amore Project. *Dermatol Reports*. 2022 Sep 26;14(3):9541.
41. Pellacani G, Bigi L, Parodi A, et al. Efficacy and Safety of Dimethyl Fumarate in Patients with Moderate-to-Severe Plaque Psoriasis: DIMESKIN-2, a Multicentre Single-Arm Phase IIIb Study. *J Clin Med*. 2022 Aug 16;11(16):4778.
42. Naldi L, Cazzaniga S. The chicken or the egg: disentangling the relationship between smoking, alcohol consumption and psoriasis using Mendelian randomization. *Br J Dermatol*. 2022;187:632-633.
43. Cazzaniga S, Heidemeyer K, Dondi L, Ronconi G, Pedrini A, Bellatreccia A, Zhong Y, Naldi L, Martini N. Prevalence of psoriatic arthritis among patients with psoriasis in Italy. *J Eur Acad Dermatol Venereol*. 2022 Aug 16.
44. May Lee M, Pierobon E, Riva G, Germi L, Feliciani C, Naldi L. Angiosarcoma and Vascular Surgery: A Case Report and Review of Literature. *Vasc Endovascular Surg*. 2022;56:762-766.
45. Sbidian E, Chaimani A, Garcia-Doval I, Doney L, Dressler C, Hua C, Hughes C, Naldi L, Afach S, Le Cleach L. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. *Cochrane Database Syst Rev*. 2022 May 23;5(5):CD011535.
46. Melandri D, Venturi M, Naldi L. Skin failure: A two-faced concept. *Dermatol Reports*. 2022 Mar 23;14(1):9406.
47. Pierobon E, Germi L, Sechi A, Trevisan G, Pezzolo E, Feliciani C, Naldi L. Keratolysis exfoliativa-like eruption induced by ranolazine. *Dermatol Reports*. 2022 Mar 22;14(1):9264.
48. Naldi L. Going global with assessing the acne burden: is the evidence worth the effort? *Br J Dermatol*. 2022;186:605.
49. Pierobon E, Sechi A, Germi L, Pezzolo E, Trevisan G, Feliciani C, Naldi L. Severe injection site reaction ensuing the first dose of mRNA COVID-19 vaccine. *Ital J Dermatol Venerol*. 2022;157:281-282.
50. Sechi A, Bassi A, Mazzatenta C, et al. Covid-19 and Covid-19 vaccine can slide along sides: a report of two cases of unilateral periflexural exanthema. *J Eur Acad Dermatol Venereol*. 2022 Epub ahead of print.

51. Koren J, Mburu S, Trigos D, Damiani G, Naldi L. Generalised pustular psoriasis: the case for rare disease and orphan designation. *Br J Dermatol*. 2022 Mar 8. Epub ahead of print.
52. Pezzolo E, Cazzaniga S, Di Leo S, Naldi L; PsoReal Study Group. Efficacy and safety of Dimethyl fumarate in comparison with conventional therapy for psoriasis: an Italian real-world clinical experience. *J Eur Acad Dermatol Venereol*. 2022 Epub ahead of print.
53. Bechman K, Cook ES, Dand N, et al. Vaccine hesitancy and access to psoriasis care in the COVID-19 pandemic: findings from a global patient-reported cross-sectional survey. *Br J Dermatol*. 2022 Epub ahead of print.
54. Sechi A, Zengarini C, Piraccini BM, et al. Treatment of retronychia: A systematic review and suggested treatment algorithm. *Dermatol Ther*. 2022;35(2):e15251.
55. Pezzolo E, Saraggi D, Naldi L. Metastatic plasma cell leukemia to the skin: A case report with review of the literature. *Dermatol Reports*. 2021 Oct 6;13(3):9099.
56. GBD 2019 Adolescent Young Adult Cancer Collaborators. The global burden of adolescent and young adult cancer in 2019: a systematic analysis for the Global Burden of Disease Study 2019. *Lancet Oncol*. 2022;23:27-52.
57. Izadi Z, Brenner EJ, Mahil SK, et al. Association Between Tumor Necrosis Factor Inhibitors and the Risk of Hospitalization or Death Among Patients With Immune-Mediated Inflammatory Disease and COVID-19. *JAMA Netw Open*. 2021 Oct 1;4(10):e2129639.
58. Cazzaniga S, Naldi L. Administrative data and scientific evidence: a lesson from France - the safety of systemic treatment for psoriasis during the COVID-19 pandemic. *Br J Dermatol*. 2022;186:7-8.
59. Sechi A, Zengarini C, Piraccini BM, Alessandrini A, Bruni F, Patrizi A, Naldi L, Starace M. Treatment of retronychia: A systematic review and suggested treatment algorithm. *Dermatol Ther*. 2021 Dec 7:e15251.
60. Sechi A, Pierobon E, Pezzolo E, et al. Abrupt onset of Sweet syndrome, pityriasis rubra pilaris, pityriasis lichenoides et varioliformis acuta and erythema multiforme: unravelling a possible common trigger, the COVID-19 vaccine. *Clin Exp Dermatol*. 2021 Oct 7:10.1111/ced.14970.
61. Fania L, Massone C, Cusano F, et al. Integrated care pathways and the hub-and-spoke model for the management of non-melanoma skin cancer: A proposal of the Italian Association of Hospital Dermatologists (ADOI). *Dermatol Reports*. 2021 Aug 5;13(2):9278.
62. Cohen AD, Vender R, Naldi L et al. Biosimilars for the treatment of patients with psoriasis: A consensus statement from the Biosimilar Working Group of the International Psoriasis Council. *JAAD Int*. 2020;1:224-230.
63. Piaserico S, Gisondi P, Cazzaniga S, Di Leo S, Naldi L. Assessing the Risk and Outcome of COVID-19 in Patients with Psoriasis or Psoriatic Arthritis on Biologic Treatment: A Critical Appraisal of the Quality of the Published Evidence. *J Invest Dermatol*. 2021 Aug 4:S0022-202X(21)01654-7.
64. Gisondi P, Cazzaniga S, Di Leo S, et al. Impact of the COVID-19 pandemic on melanoma diagnosis. *J Eur Acad Dermatol Venereol*. 2021;35:e714-e715.
65. Naldi L. Top authors in dermatology and beyond: A personal note. *Dermatol Reports*. 2021 Aug 5;13(2):9274.
66. Naldi L, Schuttelaar MA, Svensson Å, Elsner P; EDEN Fragrance Study Group. Prevalence of contact allergies in the population compared to a tertiary referral patch test clinic in Jena/Germany. *Contact Dermatitis*. 2021;85:563-571.
67. Bruze M, Engfeldt M, Elsner P, Gonçalo M, Naldi L, Schuttelaar MLA, Svedman C, Svensson Å, Ofenloch R. Validation of questionnaire algorithm based on repeated open application testing (ROAT) with the constituents of fragrance mix II: The EDEN Fragrance Study. *J Eur Acad Dermatol Venereol*. 2021 Apr 29.

68. Gisondi P, Bellinato F, Piaserico S, Di Leo S, Cazzaniga S, Naldi L. Preference for Telemedicine Versus In-Person Visit Among Patients with Psoriasis Receiving Biological Drugs. *Dermatol Ther (Heidelb)*. 2021;11:1333-1343.
69. Mahil SK, Yates M, Yiu ZZN, et al; PsoProtect study group. Describing the burden of the COVID-19 pandemic in people with psoriasis: findings from a global cross-sectional study. *J Eur Acad Dermatol Venereol*. 2021;35:e636-e640.
70. Sbidian E, Chaimani A, Garcia-Doval I, Doney L, Dressler C, Hua C, Hughes C, Naldi L, Afach S, Le Cleach L. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. *Cochrane Database Syst Rev*. 2021 Apr 19;4:CD011535.
71. Di Landro A, Naldi L, Glaser E, Paus R, Tosti A. Pathobiology questions raised by telogen effluvium and trichodynia in COVID-19 patients. *Exp Dermatol*. 2021 Apr 10. Epub ahead of print.
72. Gisondi P, Di Leo S, Bellinato F, Cazzaniga S, Piaserico S, Naldi L. Time of Onset of Selected Skin Lesions Associated with COVID-19: A Systematic Review. *Dermatol Ther (Heidelb)*. 2021 Apr 2. Epub ahead of print.
73. Rundle CW, Fortugno AP, Maghfour J, et al. Evaluating World Health Organization Essential Medicines List for Skin Disease. *Br J Dermatol*. 2021 Mar 25. Epub ahead of print.
74. Cazzaniga S, Pezzolo E, Garcovich S, Naldi L; IRHIS Study Group. Late-onset Hidradenitis Suppurativa: a cluster analysis of the National Italian Registry IRHIS. *J Am Acad Dermatol*. 2021 Mar 4:S0190-9622(21)00483-7. Epub ahead of print.
75. Naldi L. The skin as a target for SARS-CoV-2 infection: exploiting the web for suitable data. *Br J Dermatol*. 2021 Mar 4. Epub ahead of print.
76. Gisondi P, Geat D, Naldi L, Piaserico S. Insights into COVID-19 vaccination in patients with chronic plaque psoriasis on systemic treatments. *J Eur Acad Dermatol Venereol*. 2021 Mar 1. Epub ahead of print.
77. Gisondi P, Piaserico S, Bordin C, Bellinato F, Tozzi F, Alaibac M, Girolomoni G, Naldi L. The safety profile of hydroxychloroquine: major cutaneous and extracutaneous adverse events. *Clin Exp Rheumatol*. 2021 Feb 15. Epub ahead of print.
78. Piaserico S, Gisondi P, Cazzaniga S, Girolomoni G, Calzavara-Pinton PG, Naldi L. Is SARS-CoV-2 screening test indicated for psoriasis patients candidate to biologic therapy? *J Eur Acad Dermatol Venereol*. 2021 Feb 15. Epub ahead of print.
79. van Amerongen CCA, Ofenloch RF, Cazzaniga S, Elsner P, Gonçalo M, Naldi L, Svensson Å, Bruze M, Schuttelaar MLA. Skin exposure to scented products used in daily life and fragrance contact allergy in the European General Population - The EDEN Fragrance Study. *Contact Dermatitis*. 2021 Feb 11. Epub ahead of print.
80. Gisondi P, Talamonti M, Chiricozzi A, et al. Treat-to-Target Approach for the Management of Patients with Moderate-to-Severe Plaque Psoriasis: Consensus Recommendations. *Dermatol Ther (Heidelb)*. 2021 Feb;11(1):235-252. Epub 2021 Jan 11.
81. Naldi L, Massone C, Sampogna F. Dermatology Reports: A journal coming to a new life. *Dermatol Reports*. 2020 Nov 18;12(2):9015.
82. Mahil SK, Yates M, Langan SM, et al; PsoProtect and CORE-UK study groups. Risk mitigating behaviours in people with inflammatory skin and joint disease during the COVID-19 pandemic differ by treatment type: a cross-sectional patient survey. *Br J Dermatol*. 2020 Dec 23. Epub ahead of print.
83. Gisondi P, Piaserico S, Naldi L, Dapavo P, Conti A, Malagoli P, Marzano AV, Bardazzi F, Gasperini M, Cazzaniga S, Costanzo A; collaborators in the studies of COVID-19 pandemic. Incidence rates of hospitalization and death from COVID-19 in patients with psoriasis receiving biological treatment: A Northern Italy experience. *J Allergy Clin Immunol*. 2021;147:558-560.e1. Epub 2020 Nov 5.
84. Garcia-Doval I, Segovia E, Hunter H, Frew J, Naldi L. The value of case reports in pharmacovigilance. *Br J Dermatol*. 2020;183:795-796.

85. Cazzaniga S, Pezzolo E, Bettoli V, et al. Characterization of Hidradenitis Suppurativa Phenotypes: A Multidimensional Latent Class Analysis of the National Italian Registry IRHIS. **J Invest Dermatol.** 2020 Oct 21:S0022-202X(20)32184-9. Epub ahead of print.
86. Mahil SK, Dand N, Mason KJ, et al. Factors associated with adverse COVID-19 outcomes in patients with psoriasis-insights from a global registry-based study. **J Allergy Clin Immunol.** 2021 Jan;147(1):60-71. doi: 10.1016/j.jaci.2020.10.007. Epub 2020 Oct 16.
87. El Hachem M, Naldi L, Neri I, Pedone MP, Fanelli F, Galeone C. Atopic dermatitis in schoolchildren and adolescents: a critical review of Italian epidemiological data and systemic treatments. **G Ital Dermatol Venereol.** 2020 Oct 16. Epub ahead of print.
88. GBD 2019 Viewpoint Collaborators. Five insights from the Global Burden of Disease Study 2019. **Lancet.** 2020;396:1135-1159.
89. Tessari G, Maggiore U, Zaza G, et al. Mortality from cancer is not increased in elderly kidney transplant recipients compared to the general population: a competing risk analysis. **J Nephrol.** 2020;33:1309-1319.
90. Piaserico S, Gisondi P, Cazzaniga S, Naldi L. Lack of Evidence for an Increased Risk of Severe COVID-19 in Psoriasis Patients on Biologics: A Cohort Study from Northeast Italy [published online ahead of print, 2020 Aug 18]. **Am J Clin Dermatol.** 2020;1-3.
91. Naldi L, Cazzaniga S. Research Techniques Made Simple: Latent Class Analysis. **J Invest Dermatol.** 2020;140:1676-1680.
92. Naldi L, Cazzaniga S. More on Covid-19 in Immune-Mediated Inflammatory Diseases [published online ahead of print, 2020 Jul 10]. **N Engl J Med.** 2020;383:10.
93. Pezzolo E, Ciampichini R, Cazzaniga S, Sampietro G, Zucchi A, Naldi L. Psoriasis severity matters when dealing with all-cause mortality in psoriasis patients: a record linkage analysis in Northern Italy [published online ahead of print, 2020 Jul 5]. **Arch Dermatol Res.** 2020.
94. Gisondi P, Piaserico S, Bordin C, Alaibac M, Girolomoni G, Naldi L. Cutaneous manifestations of SARS-CoV-2 infection: a clinical update [published online ahead of print, 2020 Jun 25]. **J Eur Acad Dermatol Venereol.** 2020.
95. Belleudi V, Poggi FR, Perna S, et al. Drug discontinuation in pregnant women with psoriasis: The PSO-MOTHER cohort study [published online ahead of print, 2020 Jun 5]. **Pharmacoepidemiol Drug Saf.** 2020.
96. Naldi L. Risk of infections in psoriasis. A lesson to learn during the SARS-CoV-2 pandemic [published online ahead of print, 2020 Jun 15]. **Br J Dermatol.** 2020;10.1111/bjd.19190.
97. Calzavara-Pinton P, Belloni Fortina A, Bonamonte D, et al. Diagnosis and management of moderate to severe atopic dermatitis in adolescents. A Consensus. **G Ital Dermatol Venereol.** 2020 May 202 [Online ahead of print]
98. Gisondi P, Geat D, Conti A, et al. TNF- α inhibitors biosimilars as first line systemic treatment for moderate-to-severe chronic plaque psoriasis. **Expert Rev Clin Immunol.** 2020 May 18 [Online ahead of print]
99. Gisondi P, Facheris P, Dapavo P, et al. The impact of COVID-19 pandemic on patients with chronic plaque psoriasis being treated with biologic therapy: the Northern Italy experience. **Br J Dermatol.** 2020 Apr 28 [Online ahead of print]
100. Gisondi P, Piaserico S, Conti A, Naldi L. Dermatologists and SARS-CoV-2: The impact of the pandemic on daily practice. **J Eur Acad Dermatol Venereol.** 2020 Apr 22 [Online ahead of print]
101. Ingordo V, Feci L, Cazzaniga S, et al. Measuring the horizontal and vertical growth rates of superficial spreading melanoma: a pilot study with sequential digital dermoscopy. **G Ital Dermatol Venereol.** 2020 Mar 3 [Online ahead of print]

102. Antiga E, Bonciolini V, Cazzaniga S, et al. Female Patients with Dermatitis Herpetiformis Show a Reduced Diagnostic Delay and Have Higher Sensitivity Rates at Autoantibody Testing for Celiac Disease. *Biomed Res Int*. 2019 Dec 29;2019:6307035.
103. Ronconi G, Piccinni C, Dondi L, et al. Identification of cases and estimate of direct costs of unresectable and advanced cutaneous squamous cell carcinoma: real-world data from a large Italian database. *Br J Dermatol*. 2020 Jan 23. [Epub ahead of print]
104. Pezzolo E, Naldi L. Epidemiology of major chronic inflammatory immune-related skin diseases in 2019. *Expert Rev Clin Immunol*. 2020 Feb;16(2):155-166.
105. Sbidian E, Chaimani A, Afach S, et al. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. *Cochrane Database Syst Rev*. 2020 Jan 9;1:CD011535.
106. Stanganelli I, Naldi L, Cazzaniga S, et al. Sunburn-related variables, secular trends of improved sun protection and short-term impact on sun attitude behavior in Italian primary schoolchildren: Analysis of the educational campaign "Il Sole Amico" ("The sun as a friend"). *Medicine* (Baltimore). 2020;99(1):e18078.
107. Patruno C, Amerio P, Chiricozzi A, et al. Optimizing a clinical guidance for diagnosis of atopic dermatitis in adults: joint recommendations of the Italian Society of Dermatology and Venereology (SIDeMaST), Italian Association of Hospital Dermatologists (ADOI), and Italian Society of Allergological, Occupational and Environmental Dermatology (SIDAPA). *G Ital Dermatol Venereol*. 2019 Dec 16. [Epub ahead of print]
108. GBD 2017 Italy Collaborators. Italy's health performance, 1990-2017: findings from the Global Burden of Disease Study 2017. *Lancet Public Health*. 2019;4(12):e645-e657.
109. Cazzaniga S, Wiedmer C, Frangež Ž, et al. Association of Vascular Endothelial Growth Factor Subtypes with Melanoma Patients' Characteristics and Survival: A Semantic Connectivity Map Analysis. *Acta Derm Venereol*. 2020 Jan 7;100(1):adv00019.
110. Damiani G, Cazzaniga S, Conic RR, Naldi L; Psocare Registry Network. Pruritus characteristics in a large Italian cohort of psoriatic patients. *J Eur Acad Dermatol Venereol*. 2019;33:1316-1324.
111. Damiani G, Calzavara-Pinton P, Stingeni L, et al. Italian guidelines for therapy of atopic dermatitis-Adapted from consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis). *Dermatol Ther*. 2019 Nov;32(6):e13121.
112. Cazzaniga S, Anzengruber F, Augustin M, et al. Linkage between patients' characteristics and prescribed systemic treatments for psoriasis: a semantic connectivity map analysis of the Swiss Dermatology Network for Targeted Therapies registry. *J Eur Acad Dermatol Venereol*. 2019;33:2313-2318
113. Global Burden of Disease Cancer Collaboration, et al. Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2017: A Systematic Analysis for the Global Burden of Disease Study. *JAMA Oncol*. 2019 Sep 27. [Epub ahead of print]
114. Bettoli V, Cazzaniga S, Scuderi V, et al. Hidradenitis suppurativa epidemiology: from the first Italian registry in 2009 to the most recent epidemiology updates - Italian Registry Hidradenitis Suppurativa project 2. *J Eur Acad Dermatol Venereol*. 2019;33 Suppl 6:4-6.
115. Bosma AL, Spuls PI, Garcia-Doval I, et al. TREATment of ATopic eczema (TREAT) Registry Taskforce: protocol for a European safety study of dupilumab and other systemic therapies in patients with atopic eczema. *Br J Dermatol*. 2019 Aug 24. [Epub ahead of print]
116. Chatenoud L, Bertuccio P, Turati F, Galeone C, Naldi L, Chatenoud L, La Vecchia C, Bach JF; HYGIENE Study Group. Markers of microbial exposure lower the incidence of atopic dermatitis. *Allergy*. 2019 Jul 18. [Epub ahead of print].
117. Naldi L, Cazzaniga S. Mobile Teledermatology for Melanoma Detection. Response letter. *J Am Acad Dermatol*. 2019 Jul 3 [Epub ahead of print]

118. Bruze M, Engfeldt M, Ofenloch R, Elsner P, Goncalo M, Isaksson M, Naldi L, Schuttelaar ML, Svensson Å, Diepgen T. Validation of questionnaire algorithm based on repeated open application testing (ROAT) with the constituents of fragrance mix I. *Br J Dermatol*. 2019 Jun 17. doi: 10.1111/bjd.18224. [Epub ahead of print]
119. Papini M, Cusano F, Romanelli M, et al. Secukinumab shows high efficacy irrespective of HLA-Cw6 status in patients with moderate to severe plaque-type psoriasis: Results from extension phase of the SUPREME study. *Br J Dermatol*. 2019 Apr 18 [Epub ahead of print].
120. Pelloni L, Cazzaniga S, Naldi L, et al. Emergency Consultations in Dermatology in a Secondary Referral Hospital in Southern Switzerland: A Prospective Cross-Sectional Analysis. *Dermatology*. 2019 Mar 28 [Epub ahead of print].
121. Bruze M, Mowitz M, Ofenloch R, et al. The significance of batch and patch test method in establishing contact allergy to fragrance mix I-EDEN Fragrance Study Group. *Contact Dermatitis*. 2019 Feb 27. [Epub ahead of print]
122. Cazzaniga S, Castelli E, Di Landro A, et al. Mobile Teledermatology for Melanoma Detection. Assessment of Validity in the Framework of a Population-based Skin Cancer Awareness Campaign in Northern Italy. *J Am Acad Dermatol*. 2019 Feb 21 [Epub ahead of print].
123. Pezzolo E, Cazzaniga S, Colombo P, et al. Psoriasis Incidence and Lifetime Prevalence: Suggestion for a Higher Mortality Rate in Older Age-classes among Psoriatic Patients Compared to the General Population in Italy. *Acta Derm Venereol*. 2019 Jan 23. [Epub ahead of print].
124. Ingordo V, Cazzaniga S, Naldi L, et al. Atopic dermatitis in young adult Italian males: persistent and adult-onset varieties did not differ clinically and as for allergological variables. *G Ital Dermatol Venereol*. 2019 Jan 16. [Epub ahead of print].
125. Damiani G, Cazzaniga S, Naldi L; PsoReal Study Group. Use of fumaric acid derivatives (FADs) in Italian reference centres for psoriasis. *G Ital Dermatol Venereol*. 2019 Jan 9. [Epub ahead of print]
126. GBD 2017 SDG Collaborators. Measuring progress from 1990 to 2017 and projecting attainment to 2030 of the health-related Sustainable Development Goals for 195 countries and territories: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet* 2018;392:2091-2138.
127. GBD 2017 Population and Fertility Collaborators. Population and fertility by age and sex for 195 countries and territories, 1950-2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet* 2018;392:1995-2051.
128. GBD 2017 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet* 2018;392:1789-1858.
129. GBD 2017 Causes of Death Collaborators. Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017. *Lancet* 2018;392:1736-1788.
130. Ofenloch RF, Schuttelaar MLA, Svensson Å, Bruze M, Naldi L, Cazzaniga S, Elsner P, Gonçalo M, Diepgen TL. Socioeconomic Status and the Prevalence of Skin and Atopic Diseases in Five European Countries. *Acta Derm Venereol*. 2018 Nov 14 [Epub ahead of print].
131. Trifirò G, Gini R, Barone-Adesi F, Beghi E, et al. The Role of European Healthcare Databases for Post-Marketing Drug Effectiveness, Safety and Value Evaluation: Where Does Italy Stand? *Drug Saf*. 2018 Sep 29. [Epub ahead of print].
132. Mrowietz U, Barker J, Boehncke WH, et al. Clinical use of dimethyl fumarate in moderate-to-severe plaque-type psoriasis: a European expert consensus. *J Eur Acad Dermatol Venereol*. 2018 Oct; 32 Suppl 3:3-14 (Epub 2018 Sep 20).

133. Morici N, Ferri LA, Alicandro G, Tortorella G, Tondi S, Vitrella G, Bongioanni S, Ferrario M, Naldi L, La Vecchia C, Colombo D, De Servi S, Savonitto S. Psoriasis and the risk of acute coronary syndrome in the elderly. *Int J Cardiol*. 2018 Jul 26.
134. Cazzaniga S, Naldi L, Virgili A, Di Landro A, Simon D, Corazza M, Borghi A; other members of the GLS Italian Study Group. An original exploration of genital lichen sclerosis: the semantic connectivity map. *J Eur Acad Dermatol Venereol*. 2018 Jul 27 [Epub ahead of print].
135. Cazzaniga S, Scerri L, Gabbud JP, Arenberger P, Borradori L, Naldi L. Factors influencing sessions' and speakers' evaluation: an analysis of seven consecutive EADV congress editions. *J Eur Acad Dermatol Venereol*. 2018 Jul 10.[Epub ahead of print]
136. Cazzaniga S, Ballmer-Weber BK, Gräni N, Spring P, Bircher A, Anliker M, Sonntag AK, Piletta P, Huber C, Diepgen TL, Apfelbacher C, Naldi L, Borradori L, Simon D. Chronic hand eczema: A prospective analysis of the Swiss CARPE registry focusing on factors associated with clinical and quality of life improvement. *Contact Dermatitis*. 2018 Jun 25. [Epub ahead of print]
137. Peris K, Alaibac M, Argenziano G, Di Stefani A, Fargnoli MC, Frascione P, Gualdi G, Longo C, Moscarella E, Naldi L, Pellacani G, Pimpinelli N, Quaglino P, Salgarello M, Sollena P, Valentini V, Zalaudek I, Calzavara Pinton PG; Italian Group of Dermato-oncology (GIDO) of SIDeMaST. Cutaneous squamous cell carcinoma. Italian guidelines by SIDeMaST adapted to and updating EADO/EDF/EORTC guidelines. *G Ital Dermatol Venereol*. 2018 Jun 11. [Epub ahead of print]
138. GBD 2016 Healthcare Access and Quality Collaborators. Measuring performance on the Healthcare Access and Quality Index for 195 countries and territories and selected subnational locations: a systematic analysis from the Global Burden of Disease Study 2016. *Lancet*. 2018;391:2236-2271.
139. Damiani G, Manganoni A, Cazzaniga S, Naldi L; OncoSkin working group. Survey of cutaneous adverse reactions to targeted cancer therapies: value of dermatological advice. *G Ital Dermatol Venereol*. 2018 May 11. [Epub ahead of print]
140. Cazzaniga S, Naldi L, Damiani G, Atzori L, Patta F, Guidarelli G, Bettoli V. Validation of a visual-aided questionnaire for the self-assessment of hidradenitis suppurativa. *J Eur Acad Dermatol Venereol*. 2018 May 5. [Epub ahead of print].
141. Garcia-Doval I, Descalzo MA, Mason KJ, Cohen AD, Ormerod AD, Gómez-García FJ, Cazzaniga S, Feldhamer I, Ali H, Herrera-Acosta E, Griffiths CEM, Stern R, Naldi L; Psonet Network. Cumulative exposure to biologics and risk of cancer in psoriasis patients: A meta-analysis of Psonet studies from Israel, Italy, Spain, United Kingdom and Republic of Ireland. *Br J Dermatol*. 2018 May 3. [Epub ahead of print].
142. Schuttelaar MLA, Ofenloch RF, Bruze M, Cazzaniga S, Elsner P, Gonçalo M, Naldi L, Svensson Å, Diepgen TL. Prevalence of contact allergy to metals in the European general population with a focus on nickel sulfate and piercings: The EDEN Fragrance Study. *Contact Dermatitis*. 2018 Apr 10 [Epub ahead of print]
143. Shalom G, Naldi L, Lebwohl M, et al. Biological treatment for psoriasis and the risk of herpes zoster: Results from the Psoriasis Longitudinal Assessment and Registry (PSOLAR). *J Dermatolog Treat*. 2018 Apr 5. [Epub ahead of print]
144. Griffiths CEM, Augustin M, Naldi L, et al. Patient-dermatologist agreement in psoriasis severity, symptoms and satisfaction: results from a real-world multinational survey. *J Eur Acad Dermatol Venereol*. 2018 Mar 10. [Epub ahead of print].
145. Virgili A, Borghi A, Cazzaniga S, Di Landro A, Naldi L, et al. Gender differences in genital lichen sclerosis. *G Ital Dermatol Venereol*. 2018 Jan 24. [Epub ahead of print]
146. Naldi L. Biologic treatment for psoriasis and cancer: an increased risk for most cancers could not be ruled out. *Br J Dermatol*. 2018;178:19.
147. Griffiths CEM, Jo SJ, Naldi L, Romiti R, Guevara-Sangines E, Howe T, Pietri G, Gilloteau I, Richardson C, Tian H, Augustin M. A multidimensional assessment of the burden of psoriasis: Results from a multinational dermatologist and patient survey. *Br J Dermatol*. 2018 Jan 12. [Epub ahead of print]

148. Naldi L, Pezzolo E. Back to the Future: Looking at the Skin to Predict Death. A Lesson from Psoriasis. **J Invest Dermatol**. 2018;138:20-22.
149. Sbidian E, Chaimani A, Garcia-Doval I, Do G, Hua C, Mazaud C, Droitcourt C, Hughes C, Ingram JR, Naldi L, Chosidow O, Le Cleach L. Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis. **Cochrane Database Syst Rev**. 2017 Dec 22;12:CD011535. [Epub ahead of print]
150. Naldi L, Falgheri G, De Bitonto A, Di Landro A, Foiadelli L, Imberti G, Riva F, Cazzaniga S. Perception of ABC (Asymmetry, Borders and Color) Parameters in the Screening for Melanoma. Model Exercise with Experienced Dermatologists. **J Am Acad Dermatol**. 2017 Dec 18 [Epub ahead of print].
151. Svensson A, Ofenloch RF, Bruze M, Naldi L, Cazzaniga S, Elsner P, Goncalo M, Schuttelaar ML, Diepgen TL. Prevalence of skin disease in a population based sample of adults out of five European countries. **Br J Dermatol**. 2017 Dec 16 [Epub ahead of print].
152. Naldi L, Venturuzzo A, Invernizzi P. Dermatological Complications After Solid Organ Transplantation. **Clin Rev Allergy Immunol**. 2017 Nov 25. [Epub ahead of print]
153. Vinay K, Cazzaniga S, Amber KT, Feldmeyer L, Naldi L, Borradori L. Rituximab as first line adjuvant in pemphigus: retrospective analysis of the long-term outcomes in a single center. **J Am Acad Dermatol**. 2017 Nov 13. [Epub ahead of print]
154. Carrera CG, Dapavo P, Malagoli P, Naldi L, et al. PACE study: Real-life PASI 100 response with biological agents in moderate-severe psoriasis. **J Dermatolog Treat**. 2017 Oct 23:1-22. [Epub ahead of print].
155. Bissonnette R, Kerdel F, Naldi L, Papp K, et al. Evaluation of Risk of Major Adverse Cardiovascular Events With Biologic Therapy in Patients With Psoriasis. **J Drugs Dermatol**. 2017;16:1002-1013.
156. Bouwes Bavinck JN, Feltkamp MCW, Green AC, Fiocco M, Euvrard S, Harwood CA, Proby CM, Naldi L, et al. Human papillomavirus and post-transplant cutaneous squamous-cell carcinoma: a multicenter, prospective cohort study. **Am J Transplant**. 2017 Oct 11. [Epub ahead of print]
157. GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. **Lancet**. 2017;390:1211-1259.
158. GBD 2016 Causes of Death Collaborators. Global, regional, and national age-sex specific mortality for 264 causes of death, 1980-2016: a systematic analysis for the Global Burden of Disease Study 2016. **Lancet**. 2017;390:1151-1210.
159. Dragoni F, Conti R, Cazzaniga S, Colucci R, Pisaneschi L, Naldi L, Moretti S. No Association Between Vitiligo and Obesity: A Case-control Study. **Med Princ Pract**. 2017 Sep 12. doi: 10.1159/000481436. [Epub ahead of print]
160. Busard CI, Cohen AD, Wolf P, Gkalkakiotis S, Cazzaniga S, Stern RS, Hutten BA, Feldhamer I, Quehenberger F, Lichem R, Kojanova M, Adenubiova E, Addis A, Naldi, Spuls PI. Biologics combined with conventional systemic agents or phototherapy for the treatment of psoriasis: real-life data from PSONET registries. **J Eur Acad Dermatol Venereol**. 2017 Sep 12. doi: 10.1111/jdv.14583. [Epub ahead of print].
161. Modalsli EH, Åsvold BO, Snekvik I, et al. The association between the clinical diversity of psoriasis and depressive symptoms: The HUNT Study, Norway. **J Eur Acad Dermatol Venereol**. 2017 Jun 2 [Epub ahead of print].
162. Cohen AD, Wu JJ, Puig L, et al. Biosimilars for Psoriasis: Worldwide Overview of Regulatory Guidelines, Uptake and Implications for Dermatology Clinical Practice. **Br J Dermatol**. 2017 Jun 24.[Epub ahead of print].

163. Navarini AA, Burden AD, Capon F, Mrowietz U, Puig L, Köks S, Kingo K, Smith C, Barker JN; ERASPEN Network. European consensus statement on phenotypes of pustular psoriasis. **J Eur Acad Dermatol Venereol**. 2017 Jun 6. [Epub ahead of print]
164. Griffiths CEM, van der Walt JM, Ashcroft DM, Flohr C, Naldi L, Nijsten T, Augustin M. The global state of psoriasis disease epidemiology: a workshop report. **Br J Dermatol**. 2017 May 28. [Epub ahead of print]
165. GBD 2015 Healthcare Access and Quality Collaborators. GBD 2015 Healthcare Access and Quality Collaborators. Healthcare Access and Quality Index based on mortality from causes amenable to personal health care in 195 countries and territories, 1990-2015: a novel analysis from the Global Burden of Disease Study 2015. **Lancet**. 2017 May 18. [Epub ahead of print]
166. Cazzaniga S, Apfelbacher C, Diepgen T, et al; CARPE study groups of Germany and Switzerland. Patterns of chronic hand eczema: a semantic map analysis of the CARPE registry data. **Br J Dermatol**. 2017 May 12 [Epub ahead of print].
167. Naldi L. Finding a HOME for outcome measures in atopic dermatitis. **Br J Dermatol**. 2017;176:852-853.
168. Gisondi P, Altomare G, Ayala F, et al. Italian guidelines on the systemic treatments of moderate-to-severe plaque psoriasis. **J Eur Acad Dermatol Venereol**. 2017 Feb 27. [Epub ahead]
169. Naldi L. Infections and Psoriasis Treatment: More "Real-World" Data Needed with Critical Appraisal. **J Invest Dermatol**. 2017;137:271-274.
170. Bencini PL, Guida S, Cazzaniga S, Pellacani G, Galimberti MG, Bencini M, Naldi L. Risk factors for recurrence after successful treatment of warts: the role of smoking habits. **J Eur Acad Dermatol Venereol**. 2016 Dec 17. doi:10.1111/jdv.14086. [Epub ahead of print].
171. Naldi L, Cazzaniga S, di Mercurio M, Grossi E, Addis A; PSOCARE study centres. Inequalities in access to biological treatments for psoriasis: Results from the Italian Psocare Registry. **Br J Dermatol**. 2016 Dec 14. doi:10.1111/bjd.15234. [Epub ahead of print].
172. Davila-Seijo P, Garcia-Doval I, Naldi L, et al. Factors Associated with Receiving Biologics or Classic Systemic Therapy for Moderate-to-Severe Psoriasis: Evidence from the PSonet Registries. **Acta Derm Venereol**. 2016 Nov 24. [Epub ahead of print]
173. Bettoli V, Pasquinucci S, Caracciolo S, et al. The Hidradenitis suppurativa patient journey in Italy: current status, unmet needs and opportunities. **J Eur Acad Dermatol Venereol**. 2016;30:1965-1970
174. GBD 2015 Maternal Mortality Collaborators. Global, regional, and national levels of maternal mortality, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. **Lancet**. 2016;388:1775-1812.
175. GBD 2015 Child Mortality Collaborators.. Global, regional, national, and selected subnational levels of stillbirths, neonatal, infant, and under-5 mortality, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015. **Lancet**. 2016;388:1725-1774.
176. GBD 2015 DALYs and HALE Collaborators.. Global, regional, and national disability-adjusted life-year (DALYs) for 315 diseases and injuries and healthy life expectancy (HALE), 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. **Lancet**. 2016;388:1603-1658.
177. GBD 2015 Disease and Injury Incidence and Prevalence Collaborators.. Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015. **Lancet**. 2016;388:1545-1602.
178. GBD 2015 Mortality and Causes of Death Collaborators.. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015. **Lancet**. 2016;388:1459-1544.

179. Modalsli EH, Åsvold BO, Romundstad PR, Langhammer A, Hoff M, Forsmo S, Naldi L, Saunes M. Psoriasis, fracture risk and bone mineral density: The HUNT Study, Norway. *Br J Dermatol*. 2016 Oct 8. [Epub ahead of print]
180. Garcia-Doval I, Cohen AD, Cazzaniga S, Feldhamer I, Addis A, Carretero G, Ferrándiz C, Stern RS, Naldi L; Psonet Network. Risk of serious infections, cutaneous bacterial infections, and granulomatous infections in patients with psoriasis treated with anti-tumor necrosis factor agents versus classic therapies: Prospective meta-analysis of Psonet registries. *J Am Acad Dermatol*. 2016 Sep 29. [Epub ahead of print].
181. Simpson EL, Bieber T, Guttman-Yassky E, et al; SOLO 1 and SOLO 2 Investigators. Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis. *N Engl J Med*. 2016;375:2335-2348.
182. GBD 2015 SDG Collaborators.. Measuring the health-related Sustainable Development Goals in 188 countries: a baseline analysis from the Global Burden of Disease Study 2015. *Lancet*. 2016;388:1813-1850.
183. Garcia-Doval I, Ingram JR, Naldi L, Anstey A. Case reports in dermatology: loved by clinicians, loathed by editors, and occasionally important. *Br J Dermatol*. 2016;175:449-51.
184. Cazzaniga S, Castelli E, Di Landro A, Zucchi A, Naldi L. [Development of a teledermatology system for the melanoma diagnosis. The pilot experience of the project Clicca il neo]. *Recenti Prog Med*. 2016;107:440-3.
185. Doerken S, Mockenhaupt M, Naldi L, Schumacher M, Sekula P. The case-crossover design via penalized regression. *BMC Med Res Methodol*. 2016;16:103.
186. Di Landro A, Cazzaniga S, Cusano F, et al. Adult female acne and associated risk factors: Results of a multicenter case-control study in Italy. *J Am Acad Dermatol*. 2016 Aug 16.
187. Barbarot S, Rogers NK, Abuabara K, et al. Strategies used for measuring long-term control in atopic dermatitis trials: A systematic review. *J Am Acad Dermatol*. 2016 Aug 10. [Epub ahead of print]
188. Virgili A, Borghi A, Cazzaniga S, et al. New insights into potential risk factors and associations in genital lichen sclerosus: Data from a multicentre Italian study on 729 consecutive cases. *J Eur Acad Dermatol Venereol*. 2016 Aug 12. [Epub ahead of print]
189. Ziyab AH, Mukherjee N, Ewart S, et al. Filaggrin gene loss-of-function variants modify the effect of breast-feeding on eczema risk in early childhood. *Allergy*. 2016;71:1371-3.
190. GBD 2015 HIV Collaborators, Estimates of global, regional, and national incidence, prevalence, and mortality of HIV, 1980-2015: the Global Burden of Disease Study 2015. *Lancet HIV*. 2016; 3:e361-87.
191. Cazzaniga S, Naldi L, Lecchi S, Kürzinger ML, Auclert L, Gori M, Chosidow O, Hercogova J. A pilot study on the incidence of severe photosensitivity reactions leading to hospitalization linked to topical ketoprofen and other medications in selected European regions. *Pharmacol Res Perspect*. 2016 Apr 27;4(3):e00225.
192. Bencini PL, Tournalaki A, Tretti Clementoni M, Naldi L, Galimberti M. Double phase treatment with flashlamp-pumped pulsed-dye laser and long pulsed Nd:YAG laser for resistant port wine stains in adults. Preliminary reports. *G Ital Dermatol Venereol*. 2016;151:281-
193. Eissing L, Rustenbach SJ, Krensler M, Zander N, Spehr C, Radtke MA, Naldi L, Augustin M. Psoriasis registries worldwide: systematic overview on registry publications. *J Eur Acad Dermatol Venereol*. 2016 May 2. doi: 10.1111/jdv.13634. [Epub ahead of print]
194. Naldi L. Conflicts of interest among academic dermatologists: freedom or constraint? *Br J Dermatol*. 2016;174:878-80.
195. Naldi L, Cazzaniga S. Author's Reply to the Response to the Commentary of Naldi and Cazzaniga Entitled 'Are All Screening Programmes Created Equal? The Case of Melanoma'. *Dermatology*. 2016 Apr 7. [Epub ahead of print]

196. Naldi L. [Italy of miracles. Does the renaissance of Italian science pass by the Vatican?]. *Recenti Prog Med.* 2016;107:117-20
197. Christoph S, Cazzaniga S, Hunger RE, Naldi L, Borradori L, Oberholzer PA. Ultraviolet radiation protection and skin cancer awareness in recreational athletes: a survey among participants in a running event. *Swiss Med Wkly.* 2016;146:w14297.
198. Stanganelli I, Naldi L, Falcini F, et al. Parental Use and Educational Campaigns on Sunbed Use Among Teenagers and Adolescents. *Medicine* (Baltimore). 2016;95:e3034.
199. Turati F, Bertuccio P, Galeone C, Pelucchi C, Naldi L, Bach JF, La Vecchia C, Chatenoud L; HYGIENE Study Group. Early weaning is beneficial to prevent atopic dermatitis occurrence in young children. *Allergy.* 2016 Feb 19. doi: 10.1111/all.12864. [Epub ahead of print]
200. Naldi L, Cazzaniga S. Prediction of high total naevus count to estimate melanoma risk. We need more, don't we? *Br J Dermatol.* 2016;174:261-2.
201. Strober BE, Bissonnette R, Fiorentino D, Kimball AB, Naldi L, et al. Comparative effectiveness of biologic agents for the treatment of psoriasis in a real-world setting: Results from a large, prospective, observational study (Psoriasis Longitudinal Assessment and Registry [PSOLAR]). *J Am Acad Dermatol.* 2016 Feb 4. pii: S0190-9622.
202. Diepgen TL, Naldi L, Bruze M, et al. Prevalence of Contact Allergy to p-Phenylenediamine in the European General Population. *J Invest Dermatol.* 2016;136:409-15.
203. Modalsli EH, Snekvik I, Åsvold BO, Romundstad PR, Naldi L, Saunes M. Validity Self-Reported Psoriasis in a General Population: The HUNT Study, Norway. *J Invest Dermatol.* 2016;136:323-5.
204. Diphhoorn J, Cazzaniga S, Gamba C, et al. Incidence, causative factors and mortality rates of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) in northern Italy: data from the REACT registry. *Pharmacoepidemiol Drug Saf.* 2016;25:196-203.
205. Diepgen TL, Ofenloch R, Bruze M, et al. Colophony as a marker for fragrance allergy in the general European population. *Br J Dermatol.* 2016;174:695-6.
206. Paul C, Bewley A, Girolomoni G, et al. Real World Skin Clearance Rates for Biologic Treatments In Patients With Moderate to Severe Plaque Psoriasis: Interim Results From A Large Prospective, Observational Study. *Value Health.* 2015;18:A429.
207. Megna M, Bettoli V, Chimenti S, Chiricozzi A, Naldi L, et al. Hidradenitis suppurativa: guidelines of the Italian Society of Dermatology and Venereology (SIDeMaST) for the use of anti-TNF- α agents. *G Ital Dermatol Venereol.* 2015;150:731-9.
208. Johnson RW, Alvarez-Pasquin MJ, Bijl M, et al. Herpes zoster epidemiology, management, and disease and economic burden in Europe: a multidisciplinary perspective. *Ther Adv Vaccines.* 2015;3:109-20.
209. Naldi L, Cazzaniga S. Are All Screening Programmes Created Equal? The Case of Melanoma. *Dermatology.* 2015;231:294-6.
210. Diepgen TL, Ofenloch RF, Bruze M, et al. Prevalence of contact allergy in the general population in different European regions. *Br J Dermatol.* 2016;174:319-29.
211. GBD 2013 Risk Factors Collaborators. Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. *Lancet.* 2015;386:2287-323. doi:
212. Diepgen TL, Ofenloch R, Bruze M, et al. Prevalence of fragrance contact allergy in the general population of five European countries: a cross-sectional study. *Br J Dermatol.* 2015;173:1411-9.
213. GBD 2013 DALYs and HALE Collaborators. Global, regional, and national disability-adjusted life years (DALYs) for 306 diseases and injuries and healthy life expectancy (HALE) for 188 countries, 1990-2013: quantifying the epidemiological transition. *Lancet.* 2015;386:2145-91.

214. Global Burden of Disease Cancer Collaboration. The Global Burden of Cancer. *JAMA Oncol.* 2015; 1:505-27.
215. Papp K, Gottlieb AB, Naldi L, et al. Safety Surveillance for Ustekinumab and Other Psoriasis Treatments From the Psoriasis Longitudinal Assessment and Registry (PSOLAR). *J Drugs Dermatol.* 2015;14:706-14.
216. Global Burden of Disease Study 2013 Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. *Lancet.* 2015;386:743-800.
217. Hay RJ, Augustin M, Griffiths CE, et al. The global challenge for skin health. *Br J Dermatol.* 2015;172:1469-72.
218. Naldi L, Diphorn J. Seborrhoeic dermatitis of the scalp. *BMJ Clin Evid.* 2015 May 27;2015. pii: 1713.
219. Bettoli V, Naldi L, Cazzaniga S, et al. Overweight, diabetes and disease duration influence clinical severity in hidradenitis suppurativa-acne inversa: evidence from the national Italian registry. *Br J Dermatol.* 2016;174:195-7.
220. Vogel TA, Coenraads PJ, Bijkersma LM, et al. p-Phenylenediamine exposure in real life - a case-control study on sensitization rate, mode and elicitation reactions in the northern Netherlands. *Contact Dermatitis.* 2015;72:355-61.
221. Goff KL, Karimkhani C, Boyers LN, et al. The global burden of psoriatic skin disease. *Br J Dermatol.* 2015;172:1665-8.
222. Bettoli V, Naldi L, Cazzaniga S, et al. Overweight, diabetes and disease duration influence clinical severity in Hidradenitis Suppurativa - Acne Inversa. Evidence from the national Italian Registry. *Br J Dermatol.* 2015 Apr 27. doi: 10.1111/bjd.13864. [Epub ahead of print]
223. Papp K, Gottlieb AB, Naldi L, et al. WITHDRAWN: Experience with ustekinumab in patients with psoriasis enrolled in a large, multicenter, prospective, disease-based registry (Psoriasis Longitudinal Assessment and Registry [PSOLAR]). *J Am Acad Dermatol.* 2015 Jan 9. [Epub ahead of print]
224. GBD 2013 Mortality and Causes of Death Collaborators. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. *Lancet.* 2015;385:117-71.
225. Naldi L. Melanoma excision: how deep must we go? *Br J Dermatol.* 2014;171:1291-2.
226. Cazzaniga S, Lecchi S, Bruze M, et al. Development of a clinical score system for the diagnosis of photoallergic contact dermatitis using a consensus process: item selection and reliability. *J Eur Acad Dermatol Venereol.* 2014 Dec 3. [Epub ahead of print]
227. Grossi E, Cazzaniga S, Crotti S, et al. The constellation of dietary factors in adolescent acne: a semantic connectivity map approach. *J Eur Acad Dermatol Venereol.* 2014 Dec 2. [Epub ahead of print]
228. Naldi L. [Free drug samples for doctors? no, thank you!]. *Recenti Prog Med.* 2014;105:403-4.
229. Naldi L. Lifestyle intervention should be an essential component of medical care for skin disease: a challenging task. *Br J Dermatol.* 2014;171:934-5.
230. Gisondi P, Cazzaniga S, Chimenti S, et al. Latent tuberculosis infection in patients with chronic plaque psoriasis: evidence from the Italian Psocare Registry. *Br J Dermatol.* 2014 Nov 17. [Epub ahead of print]
231. Ingordo V, Cazzaniga S, Medri M, et al. To what extent is quality of life impaired in vitiligo? A multicenter study on Italian patients using the dermatology life quality index. *Dermatology.* 2014;229:240-7.

232. Ribero S, Stieger M, Quaglino P, et al. Efficacy of topical tacrolimus for oral lichen planus: real-life experience in a retrospective cohort of patients with a review of the literature. **J Eur Acad Dermatol Venereol**. 2014 Oct 13. [Epub ahead of print]
233. Gamba C, Schroeder J, Citterio A, et al. [Surveillance of severe cutaneous drug reactions: experience REACT-Lombardia]. **Recenti Prog Med**. 2014;105:379-84.
234. Boyers LN, Karimkhani C, Naghavi M, et al. Global mortality from conditions with skin manifestations. **J Am Acad Dermatol**. 2014;71:1137-1143.
235. Cazzaniga S, Conti A, Naldi L; Psoriasis Emilia Romagna Study Group. Comments on "Diet and psoriasis, Part I: Impact of weight loss interventions". **J Am Acad Dermatol**. 2014;71:829.
236. Parlar B, Blazek C, Cazzaniga S, Naldi L, et al. Treatment of lower extremity telangiectasias in women by foam sclerotherapy vs. Nd:YAG laser: a prospective, comparative, randomized, open-label trial. **J Eur Acad Dermatol Venereol**. 2015;29:549-54.
237. Murray CJ, Ortblad KF, Guinovart C, et al. Global, regional, and national incidence and mortality for HIV, tuberculosis, and malaria during 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. **Lancet**. 2014; 384:1005-70.
238. Karimkhani C, Boyers LN, Margolis DJ, et al. Comparing cutaneous research funded by the National Institute of Arthritis and Musculoskeletal and Skin Diseases with 2010 Global Burden of Disease results. **PLoS One**. 2014;9(7):e102122.
239. Naldi L, Crotti S. Epidemiology of cutaneous drug-induced reactions. **G Ital Dermatol Venereol**. 2014;149:207-18.
240. Gyulai R, Bagot M, Griffiths CE, et al. Psoriasis International Network. Current practice of methotrexate use for psoriasis: results of a worldwide survey among dermatologists. **J Eur Acad Dermatol Venereol**. 2015;29:224-31.
241. Kimball AB, Leonardi C, Stahle M, et al. Demography, baseline disease characteristics and treatment history of patients with psoriasis enrolled in a multicentre, prospective, disease-based registry (PSOLAR). **Br J Dermatol**. 2014;171:137-47.
242. Naldi L, Conti A, Cazzaniga S, Patrizi A, Pazzaglia M, Lanzoni A, Veneziano L, Pellacani G; Psoriasis Emilia Romagna Study Group. Diet and physical exercise in psoriasis: a randomized controlled trial. **Br J Dermatol**. 2014;170:634-42.
243. Ingordo V, Cazzaniga S, Raone B, et al. Circulating autoantibodies and autoimmune comorbidities in vitiligo patients: a multicenter Italian study. **Dermatology**. 2014;228:240-9.
244. Bencini PL, Cazzaniga S, Galimberti MG, et al. Variables affecting clinical response to treatment of facial port-wine stains by flash lamp-pumped pulsed dye laser: the importance of looking beyond the skin. **Lasers Med Sci**. 2014;29:1365-70.
245. Cazzaniga S, Lo Scocco G, Schincaglia E, et al. Randomized, within-patient, clinical trial comparing fluorine-synthetic fiber socks with standard cotton socks in improving plantar pustulosis. **Dermatology**. 2014;228:166-71.
246. Naldi L, Cazzaniga S, Gonçalo M, et al. EDEN Fragrance Study Group. Prevalence of self-reported skin complaints and avoidance of common daily life consumer products in selected European Regions. **JAMA Dermatol**. 2014;150:154-63.
247. Piaserico S, Cazzaniga S, Chimenti S, et al. Psocare Study Group. Efficacy of switching between tumor necrosis factor- α inhibitors in psoriasis: results from the Italian Psocare registry. **J Am Acad Dermatol**. 2014;70:257-62.e3.
248. Parazzini F, Cipriani S, Zinetti C, Chatenoud L, Frigerio L, Amuso G, Ciammella M, Di Landro A, Naldi L. Perinatal factors and the risk of atopic dermatitis: a cohort study. **Pediatr Allergy Immunol**. 2014;25:43-50.
249. Ortonne JP, Esposito M, Chimenti S, et al. Betamethasone valerate dressing is non-inferior to calcipotriol-betamethasone dipropionate ointment in the treatment of patients with mild-to-

moderate chronic plaque psoriasis: results of a randomized assessor-blinded multicentre trial. **J Eur Acad Dermatol Venereol.** 2014;28:1226-34.

250. Hay RJ, Johns NE, Williams HC, et al. The global burden of skin disease in 2010: an analysis of the prevalence and impact of skin conditions. **J Invest Dermatol.** 2014;134:1527-34.
251. Gelardi M, Iannuzzi L, Greco Miani A, Cazzaniga S, Naldi L, De Luca C, Quaranta N. Double-blind placebo-controlled randomized clinical trial on the efficacy of Aerosal in the treatment of sub-obstructive adenotonsillar hypertrophy and related diseases. **Int J Pediatr Otorhinolaryngol.** 2013;77:1818-24.
252. Bastuji-Garin S, Sbidian E, Gaudy-Marqueste C, et al. Impact of STROBE statement publication on quality of observational study reporting: interrupted time series versus before-after analysis. **PLoS One.** 2013;8(8):e64733.
253. Scirè CA, Caporali R, Sarzi-Puttini P, et al. Drug survival of the first course of anti-TNF agents in patients with rheumatoid arthritis and seronegative spondyloarthritis: analysis from the MonitorNet database. **Clin Exp Rheumatol.** 2013;31:857-63.
254. Kardaun SH, Sekula P, Valeyrie-Allanore L, et al. Drug reaction with eosinophilia and systemic symptoms (DRESS): an original multisystem adverse drug reaction. Results from the prospective RegiSCAR study. **Br J Dermatol.** 2013;169:1071-80.
255. Naldi L, Cazzaniga S. [Dermatology: experience with the disease registry for the treatment of psoriasis]. **Recenti Prog Med.** 2013;104:236-40.
256. Naldi L, Lecchi S. Floating numerators on photopatch tests: how to interpret them? **Br J Dermatol.** 2013;169:1161-2.
257. Naldi L. Melanoma management in Italy: learning from practice. A survey from the Intergruppo Italiano Melanoma. **Dermatology.** 2013;226 Suppl 1:IV.
258. Garcia-Doval I, Rustenbach SJ, Stern R, et al. Systemic psoriasis therapy shows high between-country variation: a sign of unwarranted variation? Cross-sectional analysis of baseline data from the PSONET registries. **Br J Dermatol.** 2013;169:710-4.
259. Neale RE, Weissenborn S, Abeni D, et al. Human papillomavirus load in eyebrow hair follicles and risk of cutaneous squamous cell carcinoma. **Cancer Epidemiol Biomarkers Prev.** 2013;22:719-27.
260. Sekula P, Dunant A, Mockenhaupt M, et al. RegiSCAR study group. Comprehensive survival analysis of a cohort of patients with Stevens-Johnson syndrome and toxic epidermal necrolysis. **J Invest Dermatol.** 2013;133:1197-204.
261. Cortés B, Khelifa E, Clivaz L, Cazzaniga S, Saurat JH, Naldi L, Borradori L. Mortality rate in bullous pemphigoid: a retrospective monocentric cohort study. **Dermatology.** 2012; 225:320-5.
262. Murray CJ, Vos T, Lozano R, et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. **Lancet.** 2012;380:2197-223.
263. Vos T, Flaxman AD, Naghavi M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. **Lancet.** 2012;380:2163-96.
264. Salomon JA, Vos T, Hogan DR, et al. Common values in assessing health outcomes from disease and injury: disability weights measurement study for the Global Burden of Disease Study 2010. **Lancet** 2012;380:2129-43.
265. Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. **Lancet.** 2012;380:2095-128.
266. Antonsson A, Waterboer T, Bouwes Bavinck JN, et al. EPI-HPV-UV-CA group. Longitudinal study of seroprevalence and serostability of 34 human papillomavirus types in European organ transplant recipients. **Virology.** 2013;436:91-9.

267. Antonsson A, Pawlita M, Feltkamp MC, et al. Longitudinal study of seroprevalence and serostability of the human polyomaviruses JCV and BKV in organ transplant recipients. *J Med Virol*. 2013;85:327-35.
268. Papp KA, Strober B, Augustin M, et al. PSOLAR investigators and Steering Committee. PSOLAR: design, utility, and preliminary results of a prospective, international, disease-based registry of patients with psoriasis who are receiving, or are candidates for, conventional systemic treatments or biologic agents. *J Drugs Dermatol*. 2012;11:1210-7.
269. Tessari G, Naldi L, Boschiero L, Minetti E, Sandrini S, Nacchia F, Valerio F, Rugiu C, Sassi F, Gotti E, Fonte L, Talamini G, Girolomoni G. Incidence of primary and second cancers in renal transplant recipients: a multicenter cohort study. *Am J Transplant*. 2013;13:214-21.
270. Tabolli S, Naldi L, Pagliarello C, et al. Evaluation of the impact of writing exercises interventions on quality of life in patients with psoriasis undergoing systemic treatments. *Br J Dermatol*. 2012;167:1254-64.
271. Raho G, Koleva DM, Garattini L, Naldi L. The burden of moderate to severe psoriasis: an overview. *Pharmacoeconomics*. 2012;30:1005-13.
272. Bencini PL, Cazzaniga S, Turlaki A, Galimberti MG, Naldi L. Removal of tattoos by q-switched laser: variables influencing outcome and sequelae in a large cohort of treated patients. *Arch Dermatol*. 2012;148:1364-9.
273. Augustin M, Alvaro-Gracia JM, Bagot M, Hillmann O, van de Kerkhof PC, Kobelt G, Maccarone M, Naldi L, Schellekens H. A framework for improving the quality of care for people with psoriasis. *J Eur Acad Dermatol Venereol*. 2012 Jul;26 Suppl 4:1-16. doi: 10.1111/j.1468-3083.2012.04576.x.
274. Naldi L, Cazzaniga S, Borradori L. Bullous pemphigoid: simple measures for a complex disease. *J Invest Dermatol*. 2012;132:1948-50.
275. Della Torre R, Combescure C, Cortes B, Marazza G, Beltraminelli H, Naldi L, Borradori L. Clinical presentations and diagnostic delay in bullous pemphigoid: a prospective nationwide cohort. *Br J Dermatol*. 2012 Jun 18. doi:10.1111/j.1365-2133.2012.11108.x. [Epub ahead of print]
276. Ormerod AD, Augustin M, Baker C, Chosidow O, Cohen AD, Dam TN, Garcia-Doval I, Lecluse LL, Schmitt-Egenolf M, Spuls PI, Watson KD, Naldi L. Challenges for Synthesising Data in a Network of Registries for Systemic Psoriasis Therapies. *Dermatology*. 2012 Jun 1. [Epub ahead of print]
277. Lee HY, Dunant A, Sekula P, Mockenhaupt M, Wolkenstein P, Valeyrie-Allanore L, Naldi L, Halevy S, Roujeau JC. The role of prior corticosteroids on the clinical course of Stevens-Johnson syndrome and toxic epidermal necrolysis: A case-control analysis of patients selected from the multi-national EuroSCAR and RegiSCAR studies. *Br J Dermatol*. 2012 May 28. doi: 10.1111/j.1365-2133.2012.11074.x. [Epub ahead of print]
278. Cazzaniga S, Scocco GL, Schincaglia E, Mercuri SR, Chimenti S, Saraceno R, Naldi L. Double-blind, Within-patient, Randomized, Clinical Trial Comparing Fluorine-Synthetic Fiber Socks With Standard Cotton Socks in Improving PlantarPsoriasis. *J Dermatolog Treat*. 2012 Mar 29. [Epub ahead of print]
279. Nacoti M, Cazzaniga S, Lorusso F, Naldi L, Brambillasca P, Benigni A, Corno V, Colledan M, Bonanomi E, Vedovati S, Buoro S, Falanga A, Lussana F, Barbui T, Sonzogni V. The impact of perioperative transfusion of blood products on survival after pediatric liver transplantation. *Pediatr Transplant*. 2012 Mar 19. [Epub ahead of print]
280. Di Landro A, Cazzaniga S, Parazzini F, Ingordo V, Cusano F, Atzori L, Cutri FT, Musumeci ML, Zinetti C, Pezzarossa E, Bettoli V, Caproni M, Lo Scocco G, Bonci A, Bencini P, Naldi L; GISED Acne Study Group. Family history, body mass index, selected dietary factors, menstrual history, and risk of moderate to severe acne in adolescents and young adults. *J Am Acad Dermatol*. 2012 Feb 29. [Epub ahead of print]
281. Ingordo V, Cazzaniga S, Gentile C, Iannazzone SS, Cusano F, Naldi L. Dermatology Life Quality Index score in vitiligo patients: a pilot study among young Italian males. *G Ital Dermatol Venereol*. 2012;147:83-90.

282. Suppa M, Cazzaniga S, Fagnoli MC, Naldi L, Peris K. Knowledge, perceptions and behaviours about skin cancer and sun protection among secondary school students from Central Italy. **J Eur Acad Dermatol Venereol**. 2012 Feb 20. [Epub ahead of print].
283. Gisondi P, Cazzaniga S, Chimenti S, Giannetti A, Maccarone M, Picardo M, Girolomoni G, Naldi L; Psocare Study Group. Metabolic abnormalities associated with initiation of systemic treatment for psoriasis: evidence from the Italian Psocare Registry. **J Eur Acad Dermatol Venereol**. 2012 Feb 7. [Epub ahead of print].
284. Calzavara-Pinton PG, Rossi MT, Piovaneli P, Naldi L. The main organizational changes in dermatological practice in the Lombardy Region, Italy, from 2001 to 2009. **J Eur Acad Dermatol Venereol**. 2012 Jan 13. doi:10.1111/j.1468-3083.2011.04445.x.
285. Tang YH, Mockenhaupt M, Henry A, Bounoua M, Naldi L, Le Gouvello S, Bensussan A, Roujeau JC. Poor relevance of a lymphocyte proliferation assay in lamotrigine-induced Stevens-Johnson syndrome or toxic epidermal necrolysis. **Clin Exp Allergy**. 2011 Oct 6. doi: 10.1111/j.1365-2222.2011.03875.x. [Epub ahead of print]
286. Gomez-Lira M, Tessari G, Mazzola S, Malerba G, Rugiu C, Naldi L, Nacchia F, Valerio F, Anna B, Forni A, Boschiero L, Sandrini S, Faggian G, Girolomoni G, Turco A. Analysis of the 3'UTR of the prostaglandin synthetase-2 (PTGS-2/COX-2) gene in non-melanoma skin cancer after organ transplantation. **Exp Dermatol**. 2011 Sep 6. [Epub ahead of print]
287. Sampogna F, Bouwes Bavinck JN, Pawlita M, Abeni D, Harwood C, Proby C, Feltkamp M, Euvrard S, Naldi L, Neale R, Nindl I, Pfister H, Quint W, Waterboer T. Factors associated with the seroprevalence of 26 cutaneous and two genital human papillomavirus types in organ transplant patients. **J Gen Virol**. 2011 Sep 7. [Epub ahead of print] PubMed PMID: 21900419.
288. Génin E, Schumacher M, Roujeau JC, Naldi L, Liss Y, Kazma R, Sekula P, Hovnanian A, Mockenhaupt M. Genome-wide association study of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Europe. **Orphanet J Rare Dis**. 2011 Jul 29;6:52.
289. Weissenborn S, Neale RE, Waterboer T, Abeni D, Bavinck JN, Green AC, Harwood CA, Euvrard S, Feltkamp MC, de Koning MN, Naldi L, Quint WG, Tessari G, Proby CM, Wieland U, Pfister H; EPI-HPV-UV-CA group. Beta-papillomavirus DNA loads in hair follicles of immunocompetent people and organ transplant recipients. **Med Microbiol Immunol**. 2011 Jul 27. [Epub ahead of print]
290. Naldi L, Saunes M. Methotrexate, a drug for the years to come. **Br J Dermatol**. 2011;165:230-1.
291. Proby CM, Harwood CA, Neale RE, Green AC, Euvrard S, Naldi L, Tessari G, Feltkamp MC, de Koning MN, Quint WG, Waterboer T, Pawlita M, Weissenborn S, Wieland U, Pfister H, Stockfleth E, Nindl I, Abeni D, Schegget JT, Bouwes Bavinck JN; EPI-HPV-UV-CA group. A case-control study of betapapillomavirus infection and cutaneous squamous cell carcinoma in organ transplant recipients. **Am J Transplant**. 2011;11:1498-508.
292. Wittkowski KM, Leonardi C, Gottlieb A, Menter A, Krueger GG, Tebbey PW, mBelasco J, Soltani-Arabshahi R, Gray J, Horn L, Krueger JG; International Psoriasis Council. Clinical symptoms of skin, nails, and joints manifest independently in patients with concomitant psoriasis and psoriatic arthritis. **PLoS One**. 2011;6(6):e20279. Epub 2011.
293. Cortés B, Marazza G, Naldi L, Combescure C, Borradori L; and the autoimmune bullous disease Swiss study group. Mortality of bullous pemphigoid in Switzerland: a prospective study. **Br J Dermatol**. 2011 May 17. [Epub ahead of print]
294. Rovelli F, Mercuri SR, Naldi L. [Seborrhic dermatitis in clinical practice]. **Recenti Prog Med**. 2011 Mar;102(3):126-33. [Italian]
295. Naldi L, Yawalkar N, Kaszuba A, Ortonne JP, Morelli P, Rovati S, Mautone G. Efficacy and Safety of the Betamethasone Valerate 0.1% Plaster in Mild-to-Moderate Chronic Plaque Psoriasis: A Randomized, Parallel-Group, Active-Controlled, Phase III Study. **Am J Clin Dermatol**. 2011 [Epub ahead of print]
296. Sekula P, Liss Y, Davidovici B, Dunant A, Roujeau JC, Kardaun S, Naldi L, Schumacher M, Mockenhaupt M. Evaluation of SCORTEN on a Cohort of Patients With Stevens-Johnson Syndrome

and Toxic Epidermal Necrolysis Included in the RegiSCAR Study. *J Burn Care Res*. 2011 Jan 11. [Epub ahead of print]

297. Bouwes Bavinck JN, Neale RE, Abeni D, Euvrard S, Green AC, Harwood CA, de Koning MN, Naldi L, Nindl I, Pawlita M, Pfister H, Proby CM, Quint WG, ter Schegget J, Waterboer T, Weissenborn S, Feltkamp MC; EPI-HPV-UV-CA group. Multicenter study of the association between betapapillomavirus infection and cutaneous squamous cell carcinoma. *Cancer Res*. 2010 Dec 1;70(23):9777-86. Epub
298. Rossi M, Coenraads PJ, Diepgen T, Svensson A, Elsner P, Gonçalo M, Bruze M, Naldi L. Design and Feasibility of an International Study Assessing the Prevalence of Contact Allergy to Fragrances in the General Population: The European Dermato-Epidemiology Network Fragrance Study. *Dermatology*. 2010 Sep 25.
299. Emberti Gialloreti L, Merito M, Pezzotti P, Naldi L, Gatti A, Beillat M, Serradell L, di Marzo R, Volpi A. Epidemiology and economic burden of herpes zoster and post-herpetic neuralgia in Italy: A retrospective, population-based study. *BMC Infect Dis*. 2010 Aug 3;10(1):230. [Epub ahead of print]
300. Naldi L, Mercuri SR. Chronic Pruritus Management: A Plea for Improvement - Can Itch Clinics be an option? *Dermatology*. 2010 Sep 7. [Epub ahead of print]
301. Mercuri SR, Naldi L. Potential role of ustekinumab in the treatment of chronic plaque psoriasis. *Biologics*. 2010;4:119-29.
302. Langan S, Schmitt J, Coenraads PJ, Svensson A, von Elm E, Williams H; European Dermato-Epidemiology Network (EDEN). The reporting of observational research studies in dermatology journals: a literature-based study. *Arch Dermatol*. 2010;146:534-41.
303. Ingordo V, Gentile C, Iannazzone S, Cusano F, Naldi L. Vitiligo and autoimmunity: an epidemiological study in a representative sample of young Italian males. *J Eur Acad Dermatol Venereol*. 2010 May 7. [Epub ahead of print]
304. Nijsten T, Spuls PI, Naldi L, Stern RS. The misperception that clinical trial data reflect long-term drug safety: lessons learned from Efalizumab's withdrawal. *Arch Dermatol*. 2009;145:1037-9.
305. Naldi L. [How to evaluate the benefit-risk profile of newly marketed drugs.]. *Ann Dermatol Venereol*. 2010;137:261-3. [French]
306. Naldi L, Mercuri SR. Epidemiology of comorbidities in psoriasis. *Dermatol Ther*. 2010 Mar;23:114-8.
307. Begnini A, Tessari G, Turco A, Malerba G, Naldi L, Gotti E, Boschiero L, Forni A, Rugiu C, Piaserico S, Fortina AB, Brunello A, Cascone C, Girolomoni G, Gomez-Lira M. PTCH1 gene haplotype association with basal cell carcinoma after transplantation. *Br J Dermatol*. 2010 Mar 23. [Epub ahead of print]:
308. Tessari G, Naldi L, Boschiero L, Nacchia F, Fior F, Forni A, Rugiu C, Faggian G, Sassi F, Gotti E, Fiocchi R, Talamini G, Girolomoni G. Incidence and clinical predictors of a subsequent nonmelanoma skin cancer in solid organ transplant recipients with a first nonmelanoma skin cancer: a multicenter cohort study. *Arch Dermatol*. 2010 Mar;146(3):294-9.
309. Naldi L. Malignancy concerns with psoriasis treatments using phototherapy, methotrexate, cyclosporin, and biologics: facts and controversies. *Clin Dermatol*. 2010 Jan-Feb;28(1):88-92. Review.
310. Naldi L. Scoring and monitoring the severity of psoriasis. What is the preferred method? What is the ideal method? Is PASI passé? facts and controversies. *Clin Dermatol*. 2010 Jan-Feb;28(1):67-72. Review.
311. Naldi L, Mercuri SR. Smoking and psoriasis: from epidemiology to pathomechanisms. *J Invest Dermatol*. 2009; 129:2741-3.
312. García-Doval I, Naldi L. Introduction to Clinical Research in Dermatology: The Link Between Clinical Practice and Research. *Actas Dermosifiliogr*. 2009;100(9):749-755. English, Spanish.

313. Naldi L, Svensson A, Zenoni D et al. Comparators, study duration, outcome measures and sponsorship in therapeutic trials of psoriasis: update of the EDEN Psoriasis Survey 2001-2006. **Br J Dermatol**. 2009 Sep 24. [Epub ahead of print]
314. Naldi L. Should we use body mass index to predict disease onset and severity in psoriasis? **Acta Derm Venereol**. 2009;89(5):452. PubMed PMID: 19734966.
315. Pathirana D, Ormerod AD, Saiag et al. European S3-guidelines on the systemic treatment of psoriasis vulgaris. **J Eur Acad Dermatol Venereol**. 2009;23 Suppl 2:1-70.
316. Tessari G, Naldi L, Piaserico S, et al. Incidence and clinical predictors of primary opportunistic deep cutaneous mycoses in solid organ transplant recipients: a multicenter cohort study. **Clin Transplant**. 2009 Aug 27. [Epub ahead of print]
317. Weissenborn SJ, Neale R, de Koning MN, et al. Prevalence and multiplicity of cutaneous beta papilloma viruses in plucked hairs depend on cellular DNA input. **J Virol Methods**. 2009;161:280-3.
318. Marazza G, Pham HC, Schärer L, et al. Incidence of bullous pemphigoid and pemphigus in Switzerland: a 2-year prospective study. **Br J Dermatol**. 2009 May 8. [Epub ahead of print]
319. Cazzaniga S, Sassi F, Mercuri SR, Naldi L. Prediction of Clinical Response to Excimer Laser Treatment in Vitiligo by Using Neural Network Models. **Dermatology**. 2009 Jun 18. [Epub ahead of print]
320. Naldi L, Rzany B. Psoriasis (chronic plaque). **Clin Evid (Online)**. 2009 Jan 9;2009. pii: 1706.
321. Naldi L, Sassi F. Evaluation of patient education. **Cancer Treat Res**. 2009;146:417-23.
322. Naldi L, Sassi F. Vitiligo. **N Engl J Med**. 2009;360(17):1788
323. Naldi L, Parazzini F, Gallus S; GISED Study Centres. Prevalence of atopic dermatitis in Italian schoolchildren: factors affecting its variation. **Acta Derm Venereol**. 2009;89(2):122-5.
324. de Koning MN, Weissenborn SJ, Abeni D, et al. Prevalence and associated factors of betapapillomavirus infections in individuals without cutaneous squamous cell carcinoma. **J Gen Virol**. 2009 Jul;90(Pt7):1611-21.
325. Naldi L, Chatenoud L. Registry research in dermatology. **Dermatol Clin**. 2009;27(2):185-91, vii. Review.
326. Naldi L, Raho G. Emerging drugs for psoriasis. **Expert Opin Emerg Drugs**. 2009;14(1):145-63. Review.
327. Gallus S, Naldi L. Longitudinal studies of melanocytic nevi in children: a clue to improve understanding of melanoma in adults. **Arch Dermatol**. 2009;145(2):191-3.
328. Naldi L, Rebora A. Clinical practice. Seborrheic dermatitis. **N Engl J Med**. 2009 Jan 22;360(4):387-96. Review.
329. Naldi L. The search for effective and safe disease control in psoriasis. **Lancet**. 2008;371:1311-2
330. Gallus S, Naldi L; the Oncology Study Group of the Italian Group for Epidemiologic Research in Dermatology (GISED). Distribution of congenital melanocytic naevi and congenital naevus-like naevi in a survey of 3406 Italian schoolchildren. **Br J Dermatol**. 2008 Jun 11. [Epub ahead of print]
331. Merito M, Largeron N, Cohet C, Timelli L, Boselli F, Matteelli A, Naldi L, Vittori G. Treatment patterns and associated costs for genital warts in Italy. **Curr Med Res Opin**. 2008 Oct 10. [Epub ahead of print]
332. Naldi L, Addis A, Chimenti S, Giannetti A, Picardo M, Tomino C, Maccarone M, Chatenoud L, Bertuccio P, Caggese E, Cuscito R. Impact of Body Mass Index and Obesity on Clinical Response to Systemic Treatment for Psoriasis. Evidence from the Psocare Project. **Dermatology**. 2008;217:365-373.

333. Naldi L. Assessment of the risk of fragrance allergy in the general population: challenges and methodological issues. *Drug Saf.* 2008;31(5):440-3.
334. Sassi F, Cazzaniga S, Tessari G, Chatenoud L, Reseghetti A, Marchesi L, Girolomoni G, Naldi L. Randomized controlled trial comparing the effectiveness of 308-nm excimer laser alone or in combination with topical hydrocortisone 17-butyrate cream in the treatment of vitiligo of the face and neck. *Br J Dermatol.* 2008 Aug 19. [Epub ahead of print]
335. Ingordo V, Iannazzone SS, Cusano F, Naldi L. Reproducibility of dermoscopic features of congenital melanocytic nevi. *Dermatology.* 2008;217:231-4.
336. Naldi L, Chatenoud L, Belloni A, et al. Medical history, drug exposure and the risk of psoriasis. Evidence from an Italian case-control study. *Dermatology.* 2008;216:125-30.
337. Pelucchi C, Naldi L, Di Landro A, et al. Anthropometric measures, medical history and risk of basal cell carcinoma in an Italian case-control study. *Dermatology.* 2008;216:271-6.
338. Lonjou C, Borot N, Sekula P, Ledger N, Thomas L, Halevy S, Naldi L, Bouwes-Bavinck JN, Sidoroff A, de Toma C, Schumacher M, Roujeau JC, Hovnanian A, Mockenhaupt M; for the RegiSCAR study group. A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs. *Pharmacogenet Genomics.* 2008;18:99-107.
339. Halevy S, Ghislain PD, Mockenhaupt M, Fagot JP, Bouwes Bavinck JN, Sidoroff A, Naldi L, Dunant A, Viboud C, Roujeau JC; for the EuroSCAR Study Group. Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel. *J Am Acad Dermatol.* 2007 Oct 3; [Epub ahead of print]
340. Naldi L, Gambini D. The clinical spectrum of psoriasis. *Clin Dermatol.* 2007;25:510-8.
341. Naldi L. Health-related quality of life: from health economics to bedside? *Dermatology.* 2007;215:273-6.
342. Sidoroff A, Dunant A, Viboud C, Halevy S, Bavinck JN, Naldi L, Mockenhaupt M, Fagot JP, Roujeau JC. Risk factors for acute generalized exanthematous pustulosis (AGEP)-results of a multinational case-control study (EuroSCAR). *Br J Dermatol.* 2007;157:989-96. Epub 2007 Sep 13.
343. Mockenhaupt M, Viboud C, Dunant A, Naldi L, Halevy S, Bouwes Bavinck JN, Sidoroff A, Schneck J, Roujeau JC, Flahault A. Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. *J Invest Dermatol.* 2008;128(1):35-Epub 2007 Sep 6.
344. Ingordo V, Gentile C, Iannazzone SS, Cusano F, Naldi L. The 'EpiEnlist' project: a dermo-epidemiologic study on a representative sample of young Italian males. Prevalence of selected pigmentary lesions. *J Eur Acad Dermatol Venereol.* 2007;21:1091-6.
345. Gallus S, Naldi L, Carli P, La Vecchia C; Italian Group for Epidemiologic Research in Dermatology (GISED). Nevus count on specific anatomic sites as a predictor of total body count: a survey of 3,406 children from Italy. *Am J Epidemiol.* 2007;166:472-8.
346. Farina C, Gotti E, Parma A, Naldi L, Goglio A. Pheohyphomycotic soft tissue disease caused by *Alternaria alternata* in a kidney transplant patient: a case report and literature review. *Transplant Proc.* 2007;39:1655-9. Review.
347. Lira MG, Mazzola S, Tessari G, Malerba G, Ortombina M, Naldi L, Remuzzi G, Boschiero L, Forni A, Rugiu C, Piaserico S, Girolomoni G, Turco A. Association of functional gene variants in the regulatory regions of COX-2 gene (PTGS2) with nonmelanoma skin cancer after organ transplantation. *Br J Dermatol.* 2007;157:49-57.
348. Naldi L, Chatenoud L, Bertuccio P, Zinetti C, Di Landro A, Scotti L, La Vecchia C; Oncology Cooperative Group of the Italian Group for Epidemiologic Research in Dermatology (GISED). Improving sun-protection behavior among children: results of a cluster-randomized trial in Italian elementary schools. The "SoleSi SoleNo-GISED" Project. *J Invest Dermatol.* 2007 Aug;127(8):1871-7. Epub 2007 Apr 26.

349. Bouwes Bavinck JN, Euvrard S, Naldi L, Nindl I, Proby CM, Neale R, Abeni D, Tessari GP, Feltkamp MC, Claudy A, Stockfleth E, Harwood CA; EPI-HPV-UV-CA group. Keratotic skin lesions and other risk factors are associated with skin cancer in organ-transplant recipients: a case-control study in The Netherlands, United Kingdom, Germany, France, and Italy. **J Invest Dermatol.** 2007;127(7):1647-56.
350. Ingordo V, Gentile C, Iannazzone SS, Cusano F, Naldi L. Congenital melanocytic nevus: an epidemiologic study in Italy. **Dermatology.** 2007;214(3):227-30.
351. Tartaglia S, Belloni-Fortina A, Stefano P, Tessari G, Naldi L, Tenconi R, Clementi M. The +61 A-G polymorphism of the epidermal growth factor gene is not associated with occurrence of non-melanocytic skin tumors in transplant recipients. **J Dermatol Sci.** 2007 May;46(2):147-9. Epub 2007 Jan 16.
352. Williams HC, Naldi L, Paul C, Vahlquist A, Schroter S, Jobling R. Conflicts of interest in dermatology. **Acta Derm Venereol.** 2006;86(6):485-97.
353. Tessari G, Naldi L, Boschiero L, Cordiano C, Piaserico S, Fortina AB, Cerimele D, La Parola IL, Capuano M, Gotti E, Ruggenenti P, Sassi F, Remuzzi G, Girolomoni G. Incidence and clinical predictors of Kaposi's sarcoma among 1721 Italian solid organ transplant recipients: a multicenter study. **Eur J Dermatol.** 2006 Sep-Oct;16(5):553-7.
354. Lira MG, Provezza L, Malerba G, Naldi L, Remuzzi G, Boschiero L, Forni A, Ruggiu C, Piaserico S, Alaibac M, Turco A, Girolomoni G, Tessari G. Glutathione S-transferase and CYP1A1 gene polymorphisms and non-melanoma skin cancer risk in Italian transplanted patients. **Exp Dermatol.** 2006 Dec;15(12):958-65.
355. Pelucchi C, Di Landro A, Naldi L, La Vecchia C; Oncology Study Group of the Italian Group for Epidemiologic Research in Dermatology (GISED). Risk factors for histological types and anatomic sites of cutaneous basal-cell carcinoma: an Italian case-control study. **J Invest Dermatol.** 2007;127(4):935-44.
356. Naldi L, Rzany B. Chronic plaque psoriasis. **Clin Evid.** 2006 Jun;(15):2249-83.
357. Naldi L, Randi G, Di Landro A, La Vecchia C. Red hairs, number of nevi, and risk of cutaneous malignant melanoma: results from a case-control study in Italy. **Arch Dermatol.** 2006 Jul;142(7):935-6.
358. Naldi L, Chatenoud L. Psoriasis and cancer: more than a chance link. **Ann Dermatol Venereol.** 2006;133(3):221-3.
359. Naldi L, Chatenoud L, Piccitto R, Colombo P, Placchesi EB, La Vecchia C; Prevalence of Actinic Keratoses Italian Study (PraKtis) Group. Prevalence of actinic keratoses and associated factors in a representative sample of the Italian adult population: Results from the Prevalence of Actinic Keratoses Italian Study, 2003-2004. **Arch Dermatol.** 2006 Jun;142(6):722-6.
360. Jobling R, Naldi L. Assessing the impact of psoriasis and the relevance of qualitative research. **J Invest Dermatol.** 2006 Jul;126(7):1438-40.
361. Naldi L, Manfrini R, Martin L, Deligant C, Dri P. Feasibility of a web-based continuing medical education program in dermatology: the DermoFAD experience in Italy. **Dermatology.** 2006;213(1):6-11.
362. Langan SM, Bouwes Bavinck JN, Coenraads PJ, Diepgen T, Elsner P, Grob JJ, Linder D, Naldi L, Svensson A, Williams HC; European Dermato-Epidemiology Network. Update on the activities of the European Dermato-Epidemiology Network (EDEN). **Dermatology.** 2006;213(1):1-2.
363. Ingordo V, Iannazzone SS, Cusano F, Naldi L. Dermoscopic features of congenital melanocytic nevus and Becker nevus in an adult male population: an analysis with a 10-fold magnification. **Dermatology.** 2006;212(4):354-60.
364. Randi G, Naldi L, Gallus S, Di Landro A, La Vecchia C; Oncology Study Group of the Italian Group for Epidemiologic Research in Dermatology (GISED). Number of nevi at a specific anatomical site and its relation to cutaneous malignant melanoma. **J Invest Dermatol.** 2006 Sep;126(9):2106-10.

365. Williams H, Svensson A, Diepgen T, Naldi L, Coenraads PJ, Elsner P, Grob JJ, Bouwes Bavinck JN; European Dermato-Epidemiology Network (EDEN). Epidemiology of skin diseases in Europe. *Eur J Dermatol*. 2006 Mar-Apr;16(2):212-8.
366. Griffiths CE, Iaccarino L, Naldi L, Olivieri I, Pipitone N, Salvarani C, Doria A. Psoriasis and psoriatic arthritis: immunological aspects and therapeutic guidelines. *Clin Exp Rheumatol*. 2006 Jan-Feb;24(1 Suppl 40):S72-8. Review.
367. Gallus S, Naldi L, Martin L, Martinelli M, La Vecchia C; Oncology Study Group of the Italian Group for Epidemiologic Research in Dermatology (GISED). Anthropometric measures and risk of cutaneous malignant melanoma: a case-control study from Italy. *Melanoma Res*. 2006;16(1):83-7.
368. Naldi L, Rzany B. Chronic plaque psoriasis. *Clin Evid*. 2005 Jun;(13):2070-98.
369. Naldi L, Altieri A, Imberti GL, Gallus S, Bosetti C, La Vecchia C; Oncology Study Group of the Italian Group for Epidemiologic Research in Dermatology. Sun exposure, phenotypic characteristics, and cutaneous malignant melanoma. An analysis according to different clinico-pathological variants and anatomic locations (Italy). **Cancer Causes Control**. 2005 Oct;16(8):893-9.
370. Naldi L, Chatenoud L. Psoriasis. *N Engl J Med*. 2005;353:848-50.
371. La Vecchia C, Gallus S, Naldi L. Tobacco and skin disease. *Dermatology*. 2005;211(2):81-3.
372. Naldi L, Altieri A, Imberti GL, Giordano L, Gallus S, La Vecchia C; Oncology Study Group of the Italian Group for Epidemiologic Research in Dermatology (GISED). Cutaneous malignant melanoma in women. Phenotypic characteristics, sun exposure, and hormonal factors: a case-control study from Italy. *Ann Epidemiol*. 2005;15(7):545-50.
373. Naldi L, Chatenoud L, Linder D, Belloni Fortina A, Peserico A, Virgili AR, Bruni PL, Ingordo V, Lo Scocco G, Solaroli C, Schena D, Barba A, Di Landro A, Pezzarossa E, Arcangeli F, Gianni C, Betti R, Carli P, Farris A, Barabino GF, La Vecchia C. Cigarette smoking, body mass index, and stressful life events as risk factors for psoriasis: results from an Italian case-control study. *J Invest Dermatol*. 2005;125(1):61-7.
374. Naldi L, Griffiths CE. Traditional therapies in the management of moderate to severe chronic plaque psoriasis: an assessment of the benefits and risks. *Br J Dermatol*. 2005;152(4):597-615.
375. Tessari G, Forni A, Naldi L, Faggian G, Mazzucco A, Barba A. Malignant melanoma in a candidate for heart transplantation. *Dermatology*. 2005;210(3):233-6.
376. Naldi L. A new era in the management of psoriasis? Promises and facts. *Dermatology*. 2005; 210:179-81.
377. Naldi L, Rzany B. Chronic plaque psoriasis. *Clin Evid*. 2004 Jun;(11):2140-67.
378. Naldi L, Gallus S, Tavani A, Imberti GL, La Vecchia C; Oncology Study Group of the Italian Group for Epidemiologic Research in Dermatology. Risk of melanoma and vitamin A, coffee and alcohol: a case-control study from Italy. *Eur J Cancer Prev*. 2004;13(6):503-8.
379. Ingordo V, Naldi L, Fracchiolla S, Colecchia B. Prevalence and risk factors for superficial fungal infections among Italian Navy Cadets. *Dermatology*. 2004;209(3):190-6.
380. Van Coevorden AM, Coenraads PJ, Svensson A, Bavinck JN, Diepgen TL, Naldi L, Elsner P, Williams HC; European Dermato-Epidemiology Network (Eden). Overview of studies of treatments for hand eczema-the EDEN hand eczema survey. *Br J Dermatol*. 2004 Aug;151(2):446-51. Review.
381. Bosetti C, La Vecchia C, Naldi L, Lucchini F, Negri E, Levi F. Mortality from cutaneous malignant melanoma in Europe. Has the epidemic levelled off? *Melanoma Res*. 2004 Aug;14(4):301-9.
382. Naldi L. Epidemiology of psoriasis. *Curr Drug Targets Inflamm Allergy*. 2004;3(2):121-8. Review.
383. Naldi L, Colombo P, Placchesi EB, Piccitto R, Chatenoud L, La Vecchia C; PraKtis Study Centers. Study design and preliminary results from the pilot phase of the PraKtis study: self-reported

diagnoses of selected skin diseases in a representative sample of the Italian population.

Dermatology. 2004;208(1):38-42.

384. Ingordo V, Naldi L, Colecchia B, Licci N. Prevalence of pityriasis versicolor in young Italian sailors. **Br J Dermatol**. 2003 Dec;149(6):1270-2.
385. Ingordo V, D'Andria G, Gentile C, Decuzzi M, Mascia E, Naldi L. X-linked ichthyosis in southern Italy. **J Am Acad Dermatol**. 2003 Nov;49(5):962-3.
386. Oncology Cooperative Group Of The Italian Group For Epidemiologic Research In Dermatology (GISED). Improving sun protection behaviour in children: study design and baseline results of a randomized trial in Italian elementary schools. The 'Sole Si Sole No GISED' project. **Dermatology**. 2003;207(3):291-7.
387. Ingordo V, D'Andria G, Gentile C, Decuzzi M, Mascia E, Naldi L. Frequency of X-linked ichthyosis in coastal southern Italy: a study on a representative sample of a young male population. **Dermatology**. 2003;207(2):148-50.
388. Naldi L. Counting genetic skin disease in the population. **Dermatology**. 2003;207(2):125-6.
389. Naldi L, Svensson A, Diepgen T, Elsner P, Grob JJ, Coenraads PJ, Bavinck JN, Williams H; European Dermato-Epidemiology Network. Randomized clinical trials for psoriasis 1977-2000: the EDEN survey. **J Invest Dermatol**. 2003;120(5):738-41.
390. Naldi L, Rzany B. Chronic plaque psoriasis. **Clin Evid**. 2002 Dec;(8):1688-708.
391. Braun RP, Rabinovitz HS, Krischer J, Kreusch J, Oliviero M, Naldi L, Kopf AW, Saurat JH. Dermoscopy of pigmented seborrheic keratosis: a morphological study. **Arch Dermatol**. 2002 Dec;138(12):1556-60.
392. Naldi L, Saurat JH. Dermatology launches the 'Evidence-Based Case Report' section. **Dermatology**. 2002;205(3):224-5.
393. Naldi L, Rzany B. Chronic plaque psoriasis. **Clin Evid**. 2002 Jun;(7):1488-507.
394. Naldi L. Alefacept for psoriasis: promising drug, open questions. **Arch Dermatol**. 2002;138:1238-40.
395. Campanelli A, Naldi L. A retrospective study of the effect of long-term topical application of retinaldehyde (0.05%) on the development of actinic keratosis. **Dermatology**. 2002;205(2):146-52.
396. Carli P, Naldi L, Lovati S, La Vecchia C; Oncology Cooperative Group of the Italian Group for Epidemiologic Research in Dermatology (GISED). The density of melanocytic nevi correlates with constitutional variables and history of sunburns: a prevalence study among Italian schoolchildren. **Int J Cancer**. 2002;101(4):375-9.
397. Auquier-Dunant A, Mockenhaupt M, Naldi L, Correia O, Schröder W, Roujeau JC; SCAR Study Group. Severe Cutaneous Adverse Reactions. Correlations between clinical patterns and causes of erythema multiforme majus, Stevens-Johnson syndrome, and toxic epidermal necrolysis: results of an international prospective study. **Arch Dermatol**. 2002 Aug;138(8):1019-24.
398. Naldi L. The epidemiology of fragrance allergy: questions and needs. **Dermatology**. 2002;205(1):89-97
399. Naldi L, Braun R, Saurat JH. Evidence-based dermatology: a need to reset the agenda. **Dermatology**. 2002;204(1):1-3.
400. Naldi L. Turner's syndrome, melanocytic nevi and melanoma. **Dermatology**. 2001;203(3):275.
401. Naldi L. Does clinical research help pemphigus patients? Precautions and suggestions. **Dermatology**. 2001;203(3):199-200.
402. Fagot JP, Mockenhaupt M, Bouwes-Bavinck JN, Naldi L, Viboud C, Roujeau JC; EuroSCAR Study Group. Nevirapine and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. **AIDS**. 2001 Sep 28;15(14):1843-8.

403. Naldi L, Peli L, Parazzini F, Carrel CF; Psoriasis Study Group of the Italian Group for Epidemiological Research in Dermatology. Family history of psoriasis, stressful life events, and recent infectious disease are risk factors for a first episode of acute guttate psoriasis: results of a case-control study. *J Am Acad Dermatol*. 2001 Mar;44(3):433-8.
404. Naldi L, Minelli C. Exploring the causes of cutaneous B-cell lymphoma: we should learn from the Lyme disease experience. *Dermatology*. 2000;201(4):353-5.
405. Ingordo V, Fracchiolla S, Figliola F, D'Andria G, Colecchia B, Naldi L. Prevalence and awareness of tinea pedis in Italian sailors. *Dermatology*. 2000;201(4):349-50.
406. Naldi L, Fortina AB, Lovati S, Barba A, Gotti E, Tessari G, Schena D, Diociaiuti A, Nanni G, La Parola IL, Masini C, Piaserico S, Peserico A, Cainelli T, Remuzzi G. Risk of nonmelanoma skin cancer in Italian organ transplant recipients. A registry-based study. *Transplantation*. 2000 Nov 27;70(10):1479-84.
407. Naldi L, Lovati S, Farina C, Gotti E, Cainelli T. Paecilomyces marquandii cellulitis in a kidney transplant patient. *Br J Dermatol*. 2000 Sep;143(3):647-9. Review.
408. Naldi L, Lorenzo Imberti G, Parazzini F, Gallus S, La Vecchia C. Pigmentary traits, modalities of sun reaction, history of sunburns, and melanocytic nevi as risk factors for cutaneous malignant melanoma in the Italian population: results of a collaborative case-control study. *Cancer*. 2000;88(12):2703-10.
409. Naldi L, Gallus S, Imberti GL, Cainelli T, Negri E, La Vecchia C. Sunscreens and cutaneous malignant melanoma: an Italian case-control study. *Int J Cancer*. 2000 Jun 15;86(6):879-82.
410. Naldi L, Gallus S, Imberti GL, Cainelli T, Negri E, La Vecchia C. Sunlamps and sunbeds and the risk of cutaneous melanoma. Italian Group for Epidemiological Research in Dermatology. *Eur J Cancer Prev*. 2000 Apr;9(2):133-4.
411. Naldi L, DiLandro A, D'Avanzo B, Parazzini F. Host-related and environmental risk factors for cutaneous basal cell carcinoma: evidence from an Italian case-control study. *J Am Acad Dermatol*. 2000 Mar;42(3):446-52.
412. Naldi L, Peli L, Parazzini F. Association of early-stage psoriasis with smoking and male alcohol consumption: evidence from an Italian case-control study. *Arch Dermatol*. 1999 Dec;135(12):1479-84.
413. Naldi L, Conforti A, Venegoni M, Troncon MG, Caputi A, Ghiotto E, Cocci A, Moretti U, Velo G, Leone R. Cutaneous reactions to drugs. An analysis of spontaneous reports in four Italian regions. *Br J Clin Pharmacol*. 1999;48(6):839-46.
414. Rzany B, Correia O, Kelly JP, Naldi L, Auquier A, Stern R. Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis during first weeks of antiepileptic therapy: a case-control study. Study Group of the International Case Control Study on Severe Cutaneous Adverse Reactions. *Lancet*. 1999;353:2190-4.
415. Williams HC, Po AL, Murrell D, Naldi L, Diepgen T. A systematic review of five systemic treatments for severe psoriasis. *Br J Dermatol*. 1998;139:757-8.
416. Carli P, De Giorgi V, Naldi L, Dosi G. Reliability and inter-observer agreement of dermoscopic diagnosis of melanoma and melanocytic naevi. Dermoscopy Panel. *Eur J Cancer Prev*. 1998 Oct;7(5):397-402.
417. Williams H, Adetugbo K, Po AL, Naldi L, Diepgen T, Murrell D. The Cochrane Skin Group. Preparing, maintaining, and disseminating systematic reviews of clinical interventions in dermatology. *Arch Dermatol*. 1998 Dec;134(12):1620-6.
418. Naldi L. Cigarette smoking and psoriasis. *Clin Dermatol*. 1998;16(5):571-4.
419. Rzany B, Naldi L, Schäfer T, Stern R, Williams H. The diagnosis of psoriasis: diagnostic criteria. *Br J Dermatol*. 1998 May;138(5):917.

420. Morison WL, Baughman RD, Day RM, Forbes PD, Hoenigsmann H, Krueger GG, Lebwohl M, Lew R, Naldi L, Parrish JA, Piepkorn M, Stern RS, Weinstein GD, Whitmore SE. Consensus workshop on the toxic effects of long-term PUVA therapy. **Arch Dermatol**. 1998 May;134(5):595-8.
421. Nobili A, Gebru F, Rossetti A, Schettino F, Zahn RW, Nicolis E, Macario G, Celani L, Acik VO, Farina M, Naldi L. Doctorline: a private toll-free telephone medical information service. Five years of activity: old problems and new perspectives. **Ann Pharmacother**. 1998 Jan;32(1):120-5.
422. Di Landro A, Marchesi L, Naldi L, Motta T, Cainelli T. A case of hypopigmented mycosis fungoides in a young Caucasian boy. **Pediatr Dermatol**. 1997 Nov-Dec;14(6):449-52.
423. Conforti A, Guglielmo L, Naldi L, Cocci A, Venegoni M, Leone R. Brodimoprim: adverse drug reactions from spontaneous reporting. **Br J Clin Pharmacol**. 1997 Oct;44(4):411.
424. Naldi L. Psoriasis: latest advances in understanding and novel therapeutic approaches. **Expert Opin Investig Drugs**. 1997 Jul;6(7):895-8.
425. Naldi L, Colombi A. News from dermatology. **Riv Inferm**. 1997 Jan-Mar;16(1):41-7. Italian.
426. Di Landro A, Naldi L, Locati F, Marchesi L, Cainelli T. Nodular lesions on fingertips. Diagnosis: cutaneous sarcoidosis. **Arch Dermatol**. 1996 Apr;132(4):460, 463.
427. Naldi L, Adamoli L, Frascini D, Corbetta A, Imberti L, Reseghetti A, Reciputo A, Rossi E, Cainelli T, Maserà G. Number and distribution of melanocytic nevi in individuals with a history of childhood leukemia. **Cancer**. 1996 Apr 1;77(7):1402-8.
428. Parazzini F, D'Oro LC, Naldi L, Bianchi C, Chatenoud L, Ricci E, Cainelli T, Pansera B, Mezzanotte C, Tessari GP, Locatelli A. Sexually transmitted diseases and risk of HIV infection. **Acta Derm Venereol**. 1996 Mar;76(2):147-9.
429. Cutaneous reactions to alimentary tract medications: results of a seven-year surveillance program and review of the literature. Gruppo Italiano Studi Epidemiologici in Dermatologia (GISED). **Dermatology**. 1996;193(1):11-6. Review.
430. Naldi L, Parazzini F, Peli L, Chatenoud L, Cainelli T. Dietary factors and the risk of psoriasis. Results of an Italian case-control study. **Br J Dermatol**. 1996 Jan;134(1):101-6.
431. Roujeau JC, Kelly JP, Naldi L, et al. Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. **N Engl J Med**. 1995;333:1600-7.
432. Parazzini F, Cavaliere D'oro L, Naldi L, Bianchi C, Graefembergh S, Mezzanotte C, Pansera B, Schena D, La Vecchia C, Franceschi S. Number of sexual partners, condom use and risk of human immunodeficiency virus infection. **Int J Epidemiol**. 1995 Dec;24(6):1197-203.
433. Kelly JP, Auquier A, Rzany B, Naldi L, Bastuji-Garin S, Correia O, Shapiro S, Kaufman DW. An international collaborative case-control study of severe cutaneous adverse reactions (SCAR). Design and methods. **J Clin Epidemiol**. 1995 Sep;48(9):1099-108.
434. Naldi L. Psoriasis. **Dermatol Clin**. 1995 Jul;13(3):635-47.
435. Naldi L, Locati F, Finazzi G, Barbui T, Cainelli T. Antiphospholipid syndrome associated with immunotherapy for patients with melanoma. **Cancer**. 1995 Jun 1;75(11):2784-5.
436. d'Oro LC, Parazzini F, Naldi L, La Vecchia C. Barrier methods of contraception, spermicides, and sexually transmitted diseases: a review. **Genitourin Med**. 1994 Dec;70(6):410-7.
437. Marchesi L, Naldi L, Locati F, Tribbia G, Pezzica E, Parma A, Cainelli T. Combined Clark's nevus. **Am J Dermatopathol**. 1994 Aug;16(4):364-71.
438. Naldi L, Tognoni G, Cainelli T. Analytic epidemiology in psoriasis. **J Invest Dermatol**. 1994;102:19S-23S.
439. Valsecchi R, Leighissa P, Piazzolla S, Naldi L, Cainelli T. Occupational contact dermatitis from propranolol. **Contact Dermatitis**. 1994 Mar;30(3):177.

440. Reseghetti A, Tribbia G, Locati F, Naldi L, Marchesi L. Cutaneous malignant melanoma appearing during photochemotherapy of mycosis fungoides. *Dermatology*. 1994;189(1):75-7.
441. Brevi A, Naldi L, Cainelli T, Parazzini F. Prevalence and awareness of hepatitis B virus carrier status in Italy. *Genitourin Med*. 1993 Jun;69(3):241.
442. Naldi L, Bertoni M, Cainelli T. Feasibility of a registry of pemphigus in Italy: two years experience. Gruppo Italiano Studi Epidemiologici in Dermatologia (GISED) *Int J Dermatol*. 1993 Jun;32(6):424-7.
443. Marchesi L, Naldi L, Parma A, Locati F, Cainelli T. Agminate blue nevus combined with lentigo. A variant of speckled lentiginous nevus? *Am J Dermatopathol*. 1993 Apr;15(2):162-5.
444. Naldi L, Locati F, Marchesi L, et al. Cutaneous manifestations associated with antiphospholipid antibodies in patients with suspected primary antiphospholipid syndrome: a case-control study. *Ann Rheum Dis*. 1993;52:219-22.
445. GISED. Cutaneous reactions to analgesic-antipyretics and nonsteroidal anti-inflammatory drugs. Analysis of reports to the spontaneous reporting system of the Gruppo Italiano Studi Epidemiologici in Dermatologia. *Dermatology*. 1993;186(3):164-9.
446. Bastuji-Garin S, Rzany B, Stern RS, Shear NH, Naldi L, Roujeau JC. Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. *Arch Dermatol*. 1993 Jan;129(1):92-6.
447. Naldi L, Brevi A, Cavaliere d'Oro L, Ferri C, Marchesi L, Cainelli T. Painful distal erythema and thrombocytosis. Erythromelalgia secondary to thrombocytosis. *Arch Dermatol*. 1993 Jan;129(1):105-6, 109.
448. Parazzini F, D'oro LC, Bianchi C, Mezzanotte C, Naldi L, Imberti GL, Pansera B, Cainelli T, Carlino A, Graefembergh S. Determinants of hepatitis B virus surface antigen positivity in adults attending sexually transmitted disease clinics in Italy. *Genitourin Med*. 1992 Oct;68(5):345-6.
449. Naldi L, Bronzoni M, d'Oro LC, Locati F, Marchesi L, Cainelli T. Figurate erythema, photosensitivity, and conjunctival irritation of recent onset. Subacute cutaneous lupus erythematosus (SCLE) and keratoconjunctivitis sicca. *Arch Dermatol*. 1992 Sep;128(9):1265, 1268.
450. Naldi L, Parazzini F, Brevi A, Peserico A, Veller Fornasa C, Grosso G, Rossi E, Marinaro P, Polenghi MM, Finzi A, et al. Family history, smoking habits, alcohol consumption and risk of psoriasis. *Br J Dermatol*. 1992 Sep;127(3):212-7.
451. Marchesi L, Naldi L, Di Landro A, Cavaliere d'Oro L, Brevi A, Cainelli T. Segmental lentiginosis with "jentigo" histologic pattern. *Am J Dermatopathol*. 1992 Aug;14(4):323-7. Review.
452. Naldi L, Marchesi L, Locati F, Berti E, Cainelli T. Unusual manifestations of primary cutaneous amyloidosis in association with Raynaud's phenomenon and livedo reticularis. *Clin Exp Dermatol*. 1992 Mar;17(2):117-20.
453. Naldi L, Carrel CF, Parazzini F, D'Oro LC, Cainelli T. Development of anthralin short-contact therapy in psoriasis: survey of published clinical trials. *Int J Dermatol*. 1992 Feb;31(2):126-30.
454. Naldi L, Finazzi G, Brevi A, Cavaliere d'Oro L, Locati F, Marchesi L, Cainelli T, Barbui T. Antiphospholipid antibodies and melanoma: a link? *Dermatology*. 1992;184(2):156.
455. Naldi L, Marchesi L, Locati F, Cainelli T. Multiple papular and nodular lesions in a tall woman. Nevoid basal cell carcinoma syndrome. *Arch Dermatol*. 1991 Nov;127(11):1717-8, 1720-1.
456. Parazzini F, Naldi L, Sena P, Cavaliere d'Oro L, Bianchi C, Manganoni A, Pansera B, Gramenzi A, Goglio A, Cainelli T. Risk factors for HIV infection in adults attending sexually transmitted disease clinics in Italy. *Int J Epidemiol*. 1991 Sep;20(3):758-63.
457. Naldi L, Rozzoni M, Finazzi G, Pini P, Marchesi L, Cainelli T. Etretnate therapy and thrombocytopenia. *Br J Dermatol*. 1991 Apr;124(4):395.

458. Ferri C, Reseghetti A, Veraldi S, Cusano F, Naldi L, Caputo R, Cainelli T. Bamifylline induced exanthema. *Ann Dermatol Venereol*. 1991;118(9):635-6. French.
459. GISED. Spontaneous monitoring of adverse reactions to drugs by Italian dermatologists: a pilot study. Gruppo Italiano Studi Epidemiologici in Dermatologia. *Dermatologica*. 1991;182(1):12-7.
460. GISED. Study of lichen planus conducted by the GISED: results, implications for clinical practice, prospects. Italian Group of Epidemiological Studies in Dermatology (IGESD)] *G Ital Dermatol Venereol*. 1990 Dec;125(12):563-7.
461. Naldi L, Zucchi A, Brevi A, Cavalierid'Oro L, Cainelli T. Corticosteroids and post-herpetic neuralgia. *Lancet*. 1990 Oct 13;336(8720):947.
462. Naldi L, Locati F, Marchesi L, Cainelli T. Incidence of toxic epidermal necrolysis in Italy. *Arch Dermatol*. 1990 Aug;126(8):1103-4.
463. Naldi L, Parazzini F, Cainelli T. Role of topical immunotherapy in the treatment of alopecia areata. Quality analysis of articles published between January 1977 and January 1988 about three treatments. Reading Group. *J Am Acad Dermatol*. 1990 Apr;22(4):654-6.
464. GISED. Lichen planus and liver diseases: a multicentre case-control study. Gruppo Italiano Studi Epidemiologici in Dermatologia (GISED). *BMJ*. 1990 Jan 27;300(6719):227-30.
465. Naldi L, Sena P, Cainelli T. About the association of lichen planus and psoriasis. *Dermatologica*. 1990;181(1):79-80.
466. Naldi L, Marchesi L, Finazzi G, Locati F, Cainelli T. Antiphospholipid antibodies and necrotizing purpura. *Dermatologica*. 1990;180(4):272-5.
467. Naldi L, Parazzini F, Sena P, Manganoni A, Pansera B, Cainelli T. Frequency of HIV infection in patients attending sexually transmitted disease clinics in Italy. *Int J Epidemiol*. 1989 Dec;18(4):999-1000.
468. GISED. Case-control surveillance of Stevens-Johnson syndrome and Lyell's syndrome. Presentation of the GISED project. *G Ital Dermatol Venereol*. 1989 Oct;124(10):435-40.
469. Valsecchi R, Cainelli T, Perticucci E, Gotti E, Viganò GB, Remuzzi G, Naldi L. Von Willebrand factor multimers in systemic scleroderma. *G Ital Dermatol Venereol*. 1989 May;124(5):193-6.
470. Naldi L. The Italian Group for Epidemiological Studies in Dermatology and the pilot project on the etiology of lichen planus. *G Ital Dermatol Venereol*. 1987 Mar;122(3):77-83.
471. Valsecchi R, Vicari O, Frigeni A, Foadelli L, Naldi L, Cainelli T. Familial alopecia areata--genetic susceptibility or coincidence? *Acta Derm Venereol*. 1985;65(2):175-7.
472. Moscato G, Naldi L, Candura F. Bronchial asthma due to spiramycin and adipic acid. *Clin Allergy*. 1984 Jul;14(4):355-61.
473. Moscato G, Pelissero G, Marchetti R, Naldi L, Zecca E, Prestinoni A, Piacentino G, Mussi U. Study of a group of subjects occupationally exposed to tartaric acid. *G Ital Med Lav*. 1983 Sep;5(5):193-8.
474. Moscato G, Aprile C, Gherson G, Maestrelli P, Polato R, Brunetti G, Naldi L. A new dosimeter for bronchial provocation tests: technical tests and in vitro tests. *Med Lav*. 1983;74(4):313-2.

Web-based publications

National Health System, National Library for Health. National KnowledgeWeek. Editoriale su invito. Psoriasis management: the need for independent research (<http://www.library.nhs.uk/skin/Page.aspx?pagename=EDITNALDI>)

Libri e capitoli di libri (diffusione internazionale)

1. Harald P. M. Gollnick, Jonathan Barker, Martine Bagot, Luigi Naldi (Eds.) The Challenge of Skin Diseases in Europe, EDF White Book 5th Edition.

2. Naldi L. Psoriasis. In: Dermatologic Clinics. Epidemiology. M. Weinstock ed. Saunders Co. July 1995
3. Naldi L. Inflammatory skin disorders III. Psoriasis. In: The Challenge of Dermato-epidemiology. Williams H and Strachan D eds. CRC press 1997
4. Naldi L. Alcohol, smoke and psoriasis. In: Epidemiology, causes and prevention of skin diseases. MacKie R, Stern R, Grob JJ eds. Blackwell Sci. Press 1997
5. Naldi L. Epidemiology and prevention of vascular skin disorders. In: Epidemiology, causes and prevention of skin diseases. MacKie R, Stern R, Grob JJ eds. Blackwell Sci. Press 1997
6. Naldi L. Cutaneous drug reactions. In: Dayal-Smith D, Marks R, eds. Dermatology at the Millennium. Parthenon Press 1999.
7. Williams HC, Naldi L et al. Epidemiology of skin disease in Europe. In: White Book Dermatology in Europe, European Dermatology Forum, first edition 2000, second edition 2002, third edition 2010
8. Naldi L. Vitiligo: epidemiology. In Vitiligo, problems and solutions. Lotti T and Hercogova J, eds, Marcel Dekker 2004
9. Naldi L. Dermatology. In: Textbook of Clinical Trials. Day S, Green SB, Machin D, eds. John Wiley & Sons 2004
10. Williams HC, Diepgen T, Bigby M, Herxheimer A, Naldi L, Rzany B, eds. Evidence Based Dermatology BMJ Books 2003
11. Naldi L. Epidemiology. In: Hidradenitis suppurativa. Revuz J, Jemec G, Leyden JJ eds. Springer 2006
12. Naldi L. Dermatology. In: Textbook of Clinical Trials. Day S, Green SB, Machin D, eds. John Wiley & Sons 2nd ed. 2007
13. Naldi L, Diepgen T. Epidemiology of skin cancer. In: Lim HW, Hoenigsmann H, Hawk JLM.eds. Photodermatology, Informa Healthcare, New York, 2007
14. Williams HC, Diepgen T, Bigby M, Herxheimer A, Naldi L, Rzany B, eds. Evidence Based Dermatology BMJ Books 2nd ed 2008
15. Naldi L, Sassi F. Evaluation of patient education. In Skin cancer after organ transplantation. The Scope Collaborative Group ed. Springer 2009
16. Hufford D, Naldi L. Etiological Factors in Skin Cancers: Environmental and Biological. In: Riegel DS et al, eds. Cancer of the Skin, 2nd Edition, Elsevier, London (in press 2010)
17. Naldi L. Economic and social impact. In: Psoriasis: Diagnosis and Management Editors: Wolfram Sterry, Robert Sabat, Sandra Philipp. Wiley-Blackwell (in stampa)
18. Naldi L. Epidemiology. In: Psoriasis: Diagnosis and Management Editors: Wolfram Sterry, Robert Sabat, Sandra Philipp. Wiley-Blackwell (in stampa)
19. Naldi L. Cost-effective psoriasis management. In: Psoriasis: Diagnosis and Management Editors: Wolfram Sterry, Robert Sabat, Sandra Philipp. Wiley-Blackwell (in stampa)
20. Naldi L. Psoriasis – Epidemiology. In: World Clinics in Dermatology, issue on Psoriasis, Neena Khanna, Ed. Jaypee Brothers Medical Publishers (in stampa)

Libri e capitoli di libri (in italiano)

1. Naldi L, Marchesi L. "Terapia delle malattie dermatologiche" in "Formulario Terapeutico per la Medicina Generale". Il Pensiero Scientifico 1991
2. Naldi L, Cainelli T. Epidemiologia e genetica. In: Dubertret L. ed. Psoriasi. ISED sas 1993 (edizione italiana; edizione inglese 1998)

3. Naldi L. Metodologia della ricerca clinica con aspetti di bioetica in dermatologia. In: Il Dermatologo Italiano. Vademecum 1995-6. Hippocrates Edizioni Medico-Scientifiche
4. Naldi L. Epidemiologia. In: Malattie Dermatologiche. Cainelli T, Giannetti A, Rebora A eds. McGraw-Hill Italia editore prima edizione 1997, seconda edizione 2000, terza edizione 2004, quarta edizione 2008
5. Naldi L. Patologia cutanea da farmaci. In: Malattie Dermatologiche. Cainelli T, Giannetti A, Rebora A eds. McGraw-Hill Italia editore prima edizione 1997, seconda edizione 2000
6. Naldi L. Patologia cutanea da farmaci. In: Malattie Dermatologiche. Cainelli T, Giannetti A, Rebora A eds. McGraw-Hill Italia editore 2000
- 7.
8. Naldi L. Metodi di ricerca in dermatologia. ISED sas 1998.
9. Naldi L. Epidemiologia Dermatologica. In Trattato di Dermatologia. Giannetti A ed, Piccin 2001
10. Naldi L. Epidemiologia. In La vitiligine. Lotti T ed. UTET 2000
11. Naldi L. Epidemiologia. In La Dermatite seborroica. Nuovi concetti, nuove terapie. Lotti T ed. UTET 2001
12. Naldi L, Ingordo V. Epidemiologia delle infezioni fungine superficiali in Italia. In: Le micosi superficiali. Lotti T. ed. Ed UTET 2002
13. Naldi L. Epidemiologia. In La dermatite atopica. Lotti T ed. UTET 2003
14. Naldi L. Epidemiologia. In L'acne. Lotti T ed. UTET 2002
15. Naldi L (coordinatore). La cura del dolore. La Baitta (in press)
16. Naldi L, Nobili A. Reazioni avverse da farmaco in dermatologia e allergologia. Una guida pratica. Selecta Medica 2008
17. Naldi L, Zenoni D. Reazioni avverse dermatologiche. In: Reazioni avverse a farmaci. Sospetto e diagnosi. Caputi A, De Ponti F, Pagliaro L eds. Raffaello Cortina Editore 2009
18. Naldi L. Dal Gruppo Italiano Studi Epidemiologici in Dermatologia (GISED) al Centro Studi GISED: un'evoluzione durata 25 anni . In: Storia della Dermatologia italiana. Curatore Carlo Gelmetti. Springer (in stampa)
19. Guida all'Uso dei Farmaci, Dermatologia. AIFA 2008
20. The Challenge of Skin Diseases in Europe. EDF White Book. Gollnick H, Barker J, Bagot M, Naldi L eds. 5th and 6th Editions. ABW Wissenschaftsverlag